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1INTRODUCTION
COPD is an important public health problem which is preventable as well as
treatable. It is one of the major cause of chronic morbidity and mortality throughout
the world. It is the fourth leading cause of death1. COPD has been defined by The
Global Initiative for Obstructive Lung Disease 2 (GOLD) as a disease state
characterized by airflow limitation that is fully not reversible. The chronic airflow
limitation characteristic of COPD is caused by a mixture of small airway disease
(obstructive bronchiolitis) and parenchymal destruction (emphysema), the relative
contributions vary from person to person3. The goals of drug therapy are not only to
improve lung function, but also to improve the quality of life, exercise capacity, and
to prevent exacerbations4
Theophylline is used as a bronchodilator in the pharmacotherapy of COPD for many
decades. Due to narrow therapeutic index, the plasma concentration of therapeutic
range was maintained at 10 to 20 mg/L. Theophylline has anti inflammatory effects
on small airways and reduction of hyperinflation leading to reduction in dyspnea.
The proposed mechanisms of action of Theophylline are Nonselective
Phosphodiesterase inhibition, stimulation of epinephrine release, Adenosine
receptor antagonism, increased interleukin-10 release, inhibition of mediators
(prostaglandins, tumor necrosis factor), inhibition of nuclear factor-κB, increased
apoptosis, inhibition of intracellular calcium release and increased histone
deacetylase activity5.
2Doxofylline is a newer xanthine bronchodilator that differs from theophylline.
Doxofylline has a dioxalane group in position-7. Similar to theophylline its
mechanism of action is related to the inhibition of phosphodiesterase activities, but
in contrast it has decreased affinity towards adenosine A1 and adenosine A2
receptors. The bronchodilating effect of doxofylline has been demonstrated in
bronchial asthma and chronic obstructive pulmonary disease clinical trials.
Contrary to other bronchodilators, experimental and clinical studies has shown that
doxofylline is devoid of stimulatory effects. The arrhythmogenic action of
bronchodilators have negative impact on the morbidity and mortality of patients
with respiratory diseases which is devoid in doxofylline usage.The unique
cardiovascular safety profile of doxofylline makes it unnecessary to monitor the
serum levels of the drug.
Although doxofylline shares most of the characteristics of the methylxanthine drugs,
experimental studies has shown that it is associated with less extra-respiratory
effects than theophylline6,7,8. It is suggested that decreased affinities toward
adenosine A1 and A2 receptors may account for the better safety profile of
doxofylline 9,10,11. Moreover, unlike theophylline, doxofylline does not interfere with
the influx of calcium into the cells nor does it antagonize calcium channel blocker
receptors12
There is a need to address the well known safety issues in using theophylline. We
need a better drug with greater efficacy and safety profile to treat COPD.
3Though few previous studies have advocated the efficacy and safety of doxofylline
over theophylline, the comparison of the clinical efficacy and safety profile of
doxofylline with theophylline in the Indian population has been less studied.
Therefore, the present study is designed to compare the clinical efficacy and safety
of oral theophylline and doxofylline in patients with Grade1-2 COPD (Based on
GOLD Criteria) attending the outpatient department of Chest Medicine in
Tirunelveli Medical College Hospital.
4REVIEW OF LITERATURE
DEFINITION
Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines Chronic
Obstructive Pulmonary Disease (COPD) as a common preventable and treatable
disease, characterized by persistent airflow limitation that is progressive and
associated with an increased chronic inflammatory response in the airways and
lungs to noxious particles or gases.13
HISTORICAL BACKGROUND
Emphysema was the first to be recognized when looked in a historical perspective.
Dating back to 17th and 18th centuries, clinicians recognized a condition which was
termed as abnormally “voluminous” lungs14 .In 1789, Baillie demonstrated the
classical pathologic features of emphysema in a series of illustrations.
Later renowned clinician and pathologist, Laennec described and documented
chronic bronchitis. In the year 1821, Laennec in his book, “A Treatise on the
Diseases of Chest,” describes lungs that are hyperinflated and they do not empty
well15 But, upon pathologic inspection, he noted that “the bronchus of trachea are
often accumulated with mucous fluid.” In those times, smoking was uncommon and
he attributed the primary cause of this disease to environmental and genetic factors.
It is imperative to note that Laennec identified both the characteristic features of
COPD: chronic bronchitis and emphysema.
5In 1940s, majority of the clinicians were becoming familiar with this disease entity
characterized by dyspnea on exertion with physical signs of emphysema and chronic
bronchitis in a group of patients16 .However, the reliability of diagnosis of this
condition remained a question mark until the advent of spirometer. John Hutchinson
invented the spirometer in the year 1846. It was capable of measuring only vital
capacity. Hundred years later, Tiffeneau introduced the concept of  timed vital
capacity for the measurement of airflow that allowed  spirometer to become a major
diagnostic modality for  obstruction of airflow17. In 1950s, clinicians recognized the
specific flow volume patterns in spirometry indicative of emphysema18 .In 1956, the
book of Hinshaw and Garland depicted spirograms showing obstruction of airflow
in emphysema19
In 1962,Two important scientific conferences, the CIBA Guest Symposium20 in
1959 and the American Thoracic Society (ATS) Committee on Diagnostic
Standards21 laid the foundation for the modern day definition of COPD. In the year
1965, Dr. William Briscoe was the first person to introduce the term “COPD” at the
ninth Aspen Emphysema Conference.   In 1976, Drs. Charles Fletcher and Richard
Peto in their landmark book documented that smoking cessation attenuates lung
function loss whereas continued smoking accelerates the disease and strongly
supported the link between smoking and the development of COPD22
6EPIDEMIOLOGY :
COPD is the fourth most common specific cause for death globally and predicted to
become third by 2030, if there is no interventions  addressing  the risks - tobacco
smoking, exposures to biomass fuels and environmental pollution 23-24
COPD causes a significant burden in terms of impaired quality of life and disability
25The general perception is that COPD prevalence is not well measured despite its
importance . Accurate prevalence information is necessary for various reasons such
as documentation of COPD’s impact on quality of life, costs and disability and it
also helps in public health planning 26. It is important to find out prevalence rates at
the baseline that would help researchers to monitor trends in success or failure of
control efforts.
The physiological case definition for COPD was obstruction of airflow. This was
the most common case definition that is being used in prevalence studies 27-28.
Spirometry is the single most important physiological criterion but cut-off points of
spirometry curves for detecting airflow obstruction differ in a significant manner 29.
Prevalence estimates of COPD are highly dependent on the age group but lung
function declines with age.
Prevalence estimates also vary based on smoking frequencies since smoking is a
primary risk factor for COPD. Now there are controversies attributed to the relative
impact of smoking on the COPD development in females and males with the rise in
smoking frequencies in females. The role of other inhaled exposures like biomass
fuel, ambient air pollution, occupational smoke or dust to population prevalence
7rates were not clearly determined for most countries . Global prevalence of COPD
based on Current epidemiological situation is 11.7%(8.4%–15.0%)30
Prevalence of COPD has been constantly rising in younger population groups. In
2010,the highest prevalence was estimated in the Americas 15.2%, and the lowest in
South East Asia 9.7% .The increase in percentage of COPD cases between 1990 and
2010 was the highest in the Eastern Mediterranean region (118.7%), followed by the
Africa (102.1%), and  Europe recorded the lowest increase (22.5%). In the year
2010, there were around 230 million COPD cases among urban population
(prevalence rate - 13.6%) and 153.7 million among rural population (prevalence rate
- 9.7%). The overall prevalence in men aged 30 years or more was 14.3% compared
to 7.6%  in women30. In continuation of the 2011 United Nations  high level
political declaration on non-communicable diseases31. In 2012, the World Health
Assembly , adopted a new health goal -the “25 by 25 goal” focusing on
reducing premature deaths due to COPD and other non-communicable diseases by
25% by the year 202532.
COPD was responsible for about 5% of global disability–adjusted life years totaling
76.7 million people and 5% of total deaths that is 2.9 million people  based on the
2010 Global Burden of Disease study33-34
SUBTYPES OF COPD
CHRONIC BRONCHITIS
Chronic bronchitis is defined in clinical terms as the presence of cough and sputum
production for most days over 3 months for 2 consecutive years. This clinical
8definition does not include the presence of airflow limitation. It is thought to result
from an innate immune response to inhaled toxic particles and gases, particularly in
tobacco smoke. Inflammation is present in the epithelium of the central airways and
in the mucus-producing glands in chronic bronchitis.35,36 This airway inflammation
is associated with increased mucus production, reduced mucociliary clearance, and
increased permeability of the airspace epithelial barrier.The contribution that mucus
hypersecretion makes to the airflow limitation in COPD is still uncertain. In the
early stages of COPD, its contribution is small because mucus production in
smokers with normal lung function does not appear to predict later development of
COPD.37 However, in the later stages of the disease, chronic mucus hypersecretion
may accelerate the loss of FEV1 due to an increased risk of exacerbations.38 Chronic
mucus hypersecretion may result from an inflammatory response in the submucosal
glands. Inflammatory cells release serine proteases that are potent secretagogues for
mucus.39 Oxidants derived from cigarette smoke and released from inflammatory
leukocytes may also stimulate the overproduction of mucin by induction of the
MUC5AC gene
EMPHYSEMA
Emphysema is defined as enlargement of the airspaces distal to the terminal
bronchioles, due to destruction of the alveolar walls.40 Distal airspace enlargement
with alveolar destruction reduces maximal expiratory airflow by decreasing the lung
elastic recoil. The centrilobular or centriacinar form of emphysema results from
dilatation or destruction of the respiratory bronchioles, is the type most closely
9associated with tobacco smoking, and is thought to be more associated with severe
small-airway obstruction.41 The panlobular or panacinar form of emphysema, which
is associated with α1-antitrypsin (α1-AT) deficiency, results in a more even
dilatation and destruction of the entire acinus. Although one or the other of these
types may predominate, there is great heterogeneity. The distribution of these types
of emphysema is different with an upper lobe predominance common in
centrilobular emphysema and lower lobe predominance in panlobular emphysema.
The reason for this is not clear and whether different pathogenic mechanisms are
involved is also unknown.There is a relationship between the degree of emphysema
and pack-years of smoking, but the relationship is not strong.35 Around 40% of
smokers develop substantial lung destruction from emphysema, and emphysema can
be found in some individuals who have normal lung function.35
ETIOLOGY
COPD results from a gene-environment interaction In developed countries, smoking
tobacco is the predominant risk factor. Among people with the same smoking
history, not all will develop COPD due to differences in genetic predisposition to
the disease, or in how long they live. In places where solid fuels are burned, biomass
fuel exposure is probably the dominant risk factor. Other factors associated with
COPD include second-hand tobacco exposure, age, level of education, tuberculosis,
hospitalization for childhood respiratory illness,a family history of COPD, and the
number of years worked in dusty jobs.42 Clearly, multiple risk factors may be
10
present in a single individual.. Risk factors for COPD may also be related in more
complex ways.  Risk factors for the development of COPD are environmental and
host based .
RISK FACTORS
ENVIRONMENTAL FACTORS
SMOKING
BIOMASS FUEL EXPOSURE
AMBIENT AIR POLLUTION
OCCUPATIONAL EXPOSURES
LOW SOCIOECONOMIC STATUS
HOST FACTORS
GENETIC
ASTHMA AND AIRWAY HYPERREACTIVITY
RECURRENT INFECTIONS
TOBACCO SMOKING
Globally, cigarette smoking is the most commonly encountered risk factor for
COPD. Smoking during pregnancy poses a risk for the fetus, by affecting lung
growth and development in utero.43,44 Smoking in childhood and adolescence leads
to stunting of lung growth and earlier decline in lung function than in nonsmokers.45
Adult cigarette smokers have a higher prevalence of respiratory symptoms, lower
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lung function, a greater annual rate of decline in FEV1, a greater loss of lung
density, and a greater COPD mortality rate than nonsmokers.46,47 Deterioration of
FEV1 correlates with pack-years of smoking, but the relationship between amount
of smoking and risk of COPD is unpredictable on an individual basis Among former
smokers, the age at smoking cessation affects the subsequent rate of deterioration of
lung function. The rate is closest to never smokers for those who quit prior to age
30,but even for those who quit after age 40, deterioration is less than in continued
smokers.The crucial factor seems to be the amount smoked and the extent of
inhalation.48 Filtered cigarettes do not differ significantly from cigarettes without
filters, and other types of tobacco and marijuana are also risk factors for COPD.49,50
Smoking cessation had, in several studies, been shown to be associated with both a
lower prevalence of respiratory symptoms and a slower decline in FEV1, studies.48
In India and other Southeast Asian countries, bidi smoking is more common than
cigarette smoking. Bidis are made up of tobacco wrapped in tendu leaf. Although
the amount of nicotine in a bidi is one-fourth that of a cigarette, the amount of tar is
roughly five times greater. From COPD point of view, one bidi is as harmful as one
cigarette. Due to the low combustibility of the tendu leaf wrapper, bidi smokers
inhale more often and more deeply, thereby breathing greater amounts of tar.51
Cigarette smoke contains two very different populations of free radicals, one in the
tar and one in the gas phase. The tar phase contains several relatively stable free
radicals, the principal radical being quinone/ hydroquinone (Q/QH2). The gas phase
of cigarette smoke contains small oxygen and carbon-centered radicals that are more
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reactive than are the tar-phase radicals. One of the important mechanism through
which tobacco smoke exerts its harmful effects on the lungs is the oxidative stress
caused by reactive oxygen species. New evidence suggests that up to 50% of
smokers develop COPD.52 The risk of COPD also occurs amongst people who are
exposed to second-hand smoke.53,54
Environmental Tobacco Smoke Exposure or Second-Hand Smoke
Environmental tobacco smoke exposure (ETS) is implicated in loss of many years
of life of adults and children but COPD, specifically, as a cause of the life
shortening due to ETS is not clear55 Controlled experimental studies with normal
volunteers indicate that short-term exposures to ETS at levels comparable to those
in real-life situations have effects on serum cytokine levels and pulmonary function
that if recurrent or chronic might translate into COPD.56,57 However, when smoking
and other risk factors are controlled both workplace and home ETS but not prenatal
ETS increase the risk of development of COPD.58 Data regarding in utero effects of
maternal smoking on lung growth and subsequent risk of childhood wheezing or
asthma are becoming evident. However, doubt exists regarding the quantitative
impact on the development of COPD in individuals with only prenatal exposure. It
seems likely that similar to cystic fibrosis, individuals with enhanced genetic risk
factors could be adversely modulated by ETS,59 but to date no definitive proof of
gene-by-environment interactions for ETS have been demonstrated. The data does
not suggest that ETS is harmless but rather it is less definitively causal of COPD as
an independent risk than chronic smoking or occupational exposures.58 Avoidance
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in individuals with existing lung disease is clearly indicated given the association
with exacerbation. The attitude that there is no risk-free dose of ETS, is likely the
safest approach; this applies to all ETS-related diseases and not just COPD.55
Biomass fuel exposure
Biomass fuel exposure is the term covering exposure to smoke from wood, animal
dung, crop residues, and coal, typically burned in open fires or primitive stoves.
Biomass fuel exposure is an important source of indoor air pollution in undeveloped
countries there is increasing evidence that this exposure is an important risk factor
for COPD.60-62
It is estimated that about half of the global population (3 billion people) live in
homes that use biomass fuel for cooking and heating purposes. Burning of biomass
solid fuel emits very high levels of indoor air pollutants, both particulate matter as
well as the gaseous pollutants. Many of these homes are poorly ventilated, exposing
these individuals to very high levels of indoor air pollutants. Women, young girls
and small children are exposed for the longest duration because they spend more
time in close vicinity to the biomass smoke. During their lifetime, women are
exposed for around 30–40 years, which is equivalent to 60,000 hours of exposure to
biomass smoke or inhaling a total volume of 25 million liters of highly polluted
indoor air.63 The levels of indoor air pollutants, encountered in homes that use
biomass fuel, are several orders higher than the levels in the most polluted urban
cities in the world. These pollutants have the potential to produce intense oxidative
stress in the lungs and the elastolytic effects of these pollutants have been found to
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be worse than those caused due to tobacco smoke. The exposure to biomass smoke
induces the same amount of risk of developing COPD as tobacco smoke. As 3
billion people are exposed to biomass smoke worldwide as compared to 1.1 billion
smokers, biomass smoke is likely to be the biggest risk factor of COPD.63
OUTDOOR AIR POLLUTION
Ambient air pollution is a growing problem in most urban cities of the world. Over
the last few decades, air pollution in most cities in the developed countries has
decreased appreciably due to the advent of strict legislation and improvements in
engine technology, but it continues to increase markedly in most of the cities of the
developing countries. Both the gaseous and particulate matter components of urban
ambient air pollutants have been shown to be associated with increasing respiratory
morbidity and cardiovascular mortality. One of the earliest studies that investigated
an association between ambient air pollution and COPD was by Fairbairn64 in 1958,
who reported that postmen from England and Wales who worked in areas with
higher outdoor air pollution levels, had a greater prevalence of COPD than those
who worked in areas with lower ambient air pollution levels. A subsequent study
from the United Kingdom showed that postmen who worked in more polluted cities
had lower lung function values than those who worked in less polluted areas.65
Similar observations were later reported in the general population.66 More recently,
living in areas closer to roads with heavy motor vehicular traffic have been shown to
be associated with significant decrements in lung function,67 and increased
prevalence of COPD in women.68
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OCCUPATIONAL EXPOSURES
The association between occupational exposures and COPD has been observed for
at least four decades. Earlier studies revealed that exposure to toxic gases at
workplace,69 grain dust in farms,70 and to dust and fumes in factories,71 were
strongly associated with the risk of development of COPD. In 2003, the American
Thoracic Society conducted a systematic epidemiological review of occupational
factors associated with the development of COPD and reported that approximately
15% of COPD may be attributable to workplace exposure.72 Farming as an
occupation has been shown to be strongly associated with COPD.  The risk of
COPD, attributable to farming was 7.7% and that around 30% of the farmers had at
least mild COPD. Longitudinal studies have documented the association between
COPD and occupational exposures in coal miners, hard rock miners, tunnel workers
and concrete manufacturing workers. In heavily exposed workers, the effect of dust
exposure may be even greater than that of cigarette smoking alone.73 Construction
workers exposed to fumes and mineral dust have been shown to have a significantly
higher risk of death due to COPD.74 Prolonged exposure to silica in occupations,
such as the construction industry, brick manufacturing, gold mining and in iron and
steel foundries  is also strongly associated with the development of COPD.75 The
burden of occupational COPD is likely to be high in countries of low and middle
income, where occupational exposures to dust and fumes could be greater than in
high-income nations, because of less stringent laws and lack of adequate facilities
for reducing the exposures.
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Childhood Lower Respiratory Tract Infections
Since the status of lung function in very early childhood predicts ventilatory
function many years later,76 it is plausible that lower respiratory tract infections
(LRIs) during childhood might adversely affect lung development and increase the
risk of developing COPD later in life. However, lung function in children who had
pneumonia up to age 2 infrequently had reduced lung function 10 years after the
infection.77 If there was a ventilatory defect, it was most often restrictive. Where
reduced airflow was observed, an adenovirus was the predominant class of
pathogens responsible for the pneumonia. It is notable that COPD exacerbations
may leave only a minor lasting effect on airflow. Continued smokers enrolled in the
Lung Health Study had only an additional loss of 7 mL of FEV1 per year for those
having one exacerbation per year, while among those who had quit smoking,
exacerbations had no permanent effect on the FEV1.78
PULMONARY TUBERCULOSIS
Pulmonary tuberculosis  has been shown to be associated with chronic airflow
obstruction, particularly of the COPD phenotype, at the time of diagnosis,79 during
treatment,80 and several years after the completion of treatment.81 The amount of
airflow obstruction is related to the extent of the disease determined radiologically,
the amount of sputum produced and the length of time after the diagnosis or
completion of treatment.82 Apart from the airway fibrosis that may follow tubercular
infections, the immune response to mycobacteria may enhance the airway
inflammation that is typical of COPD. More than 2 billion people, equal to one-third
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of the world’s population, are infected with tubercle bacilli and an estimated 9.2
million new cases of tuberculosis are detected every year; 80% of them are present
in 22countries of the world.83Countries from Asia, Africa and Latin America have a
particularly high burden of pulmonary tuberculosis. The cumulative burden of
COPD associated with pulmonary tuberculosis is, therefore, likely to be much
greater than previously believed, especially in the developing countries.84
HUMAN IMMUNODEFICIENCY VIRUS INFECTION
Individuals with human immunodeficiency virus (HIV) who smoke have an
increased risk of COPD or more specifically emphysema development.85 The risk
appears to be modulated by activation of alveolar macrophages with evidence of
enhanced production of matrix metalloproteinases (MMPs) in these individuals.86
Although HIV can infect macrophages,87 it is unclear if this is a direct alteration due
to HIV infection or a response to some downstream alteration of the suppression of
innate immune responses, like chronic Pneumocystis infection.88 The occurrence of
COPD and pulmonary hypertension in smokers with HIV appears to be more
common in individuals with a high viral load and lower CD4 cell counts and not an
adverse consequence of antiretroviral therapy.89 But emphysema is not reversible
and relation to viral load or recovery of CD4 cell counts is not direct.
ASTHMA AND BRONCHIAL HYPERREACTIVITY
Asthma and COPD are generally viewed as two different diseases with a variable
overlap.90 However, asthma may also be viewed as a risk factor for the development
of COPD. In the Tucson study, adults with asthma were found to have a 12 fold
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higher risk of acquiring COPD over time than those without asthma, after adjusting
for smoking.91 A Dutch study of people with asthma found that 20% of subjects
developed irreversible airflow limitation92 and, in a Danish longitudinal population
study, self-reported asthma was associated with an excess loss of FEV1.93
In the European Community Respiratory Health Survey, bronchial hyper
responsiveness was second only to cigarette smoking as the leading risk factor for
COPD, responsible for 15% of the population attributable risk.94 This is in
accordance with previous studies showing a strong impact of bronchial
hyperresponsiveness on FEV1 decline, also in the absence of asthma.95
GENETIC FACTORS
Although COPD is predominantly an environmental lung disease, it is clear that
genetic susceptibility is also important. Recent studies have indicated that COPD
can run in families, and for this several potential genes have been identified96 A
significant familial risk of airflow limitation has been observed in smoking siblings
of patients with severe COPD,97 suggesting that genetic, together with
environmental factors, could influence this susceptibility. Deficiency of A1AT, a
major circulating inhibitor of serine proteases, is the best documented genetic risk
factor for developing emphysema.98 Although A1AT deficiency is relevant to only a
small part of the world’s population, its potentiating effect on the harmful effects of
smoking illustrates the interaction between genes and environmental exposures
leading to COPD. Other single genes have some effect on the risk of developing
COPD, including the alpha nicotinic acetylcholine receptor, as well as the hedgehog
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interacting protein gene, the FAM13 gene, and the gene encoding MMP12. A few
other genes have been implicated, but there remains a discrepancy between findings
from analyses of COPD and lung function, as well as between genome-wide
association study (GWAS) analyses and candidate gene analyses.99 In addition, none
of the genes yet identified by GWAS in patients with COPD overlap with genes
found to have an effect on the level of lung function.100
LOW SOCIOECONOMIC STATUS
Poor socioeconomic status is a risk factor independently associated with COPD and
is likely to be indicative of other factors such as intrauterine growth retardation,
poor nutrition (low intake of antioxidants), housing conditions, childhood
respiratory tract infections, exposure to tobacco smoke, occupational risks, and
biomass smoke and other indoor air pollutants. These factors might collectively
contribute to the risk of COPD.101 Socioeconomic status should therefore be treated
as an independent risk factor for COPD.
Age and Gender
Age is often listed as a risk factor for COPD. It is unclear if healthy aging as such
leads to COPD or if age reflects the sum of cumulative exposures throughout life. In
the past, most studies showed that COPD prevalence and mortality were greater
among men than women but data from developed countries102 show that the
prevalence of the disease is now almost equal in men and women, probably
reflecting the changing patterns of tobacco smoking. Some studies have even
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suggested that women are more susceptible to the effects of tobacco smoke than
men103
PATHOGENETIC MECHANISMS
COPD represents the clinical expression of complex alterations in structure and
function of alveolar tissue and small airways. Many processes at the tissue and
cellular levels can be implicated, including inflammation, cell proliferation,
apoptosis, altered phenotype of lung cells, and remodeling of the extracellular
matrix . Numerous mediators, most notably proteinases, oxidants, and cytokines, are
involved in these processes. Studies in genetically altered mice have proven
invaluable in helping to elucidate the pathogenesis of COPD, especially
emphysema. factors that recruit inflammatory cells to the lungs. The various
inflammatory cells that accumulate in the peripheral tissues of the lungs release
proteinases and oxidants that damage or degrade extracellular matrix in the walls of
alveoli, alveolar ducts, and respiratory bronchioles. In addition, agents in smoke and
those released by inflammatory cells inactivate proteinase inhibitors such as α1-
antitrypsin, and cause senescence and apoptosis of lung cells that produce
extracellular matrix. Products of the damaged extracellular matrix, such as peptides
of degraded elastin, are chemotactic for inflammatory cells; thus degradation of the
extracellular matrix may lead to a feedback loop that perpetuates inflammation.
These matrix-derived products may also elicit immune responses that lead to
destruction of extracellular matrix. Not shown are the role of mechanical forces that
may also promote deformation of lung tissue.
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INFLAMMATION
Innate Immune Responses
As reflected in the definition of COPD, inflammation occupies a central role in
current thinking about the pathogenesis of COPD. The inflammation paradigm is
that smoking and other types of inhaled irritants lead to recruitment of innate
inflammatory cells to the lungs and airways and that products of these recruited
cells injure lung tissue and disrupt normal mechanisms of lung repair. Indeed,
inflammation is prominent in airways and lung parenchyma in biopsies, surgical
specimens, and postmortem material from individuals with COPD.104 Other
indicators of inflammation are increased inflammatory cells in bronchoalveolar
lavage fluid (BALF)105 and sputum and increased volatile products of inflammatory
cells in exhaled breath.106 Systemic inflammation is also present in current smokers,
with elevations in white blood cell counts, neutrophil subsets, or liver-derived acute
phase reactants.107 Inflammatory cells associated with COPD in the lung include
predominantly neutrophils, macrophages, and sometimes eosinophils, but also
dendritic cells and lymphocytes .Once the inflammatory process is initiated by
smoking the process may persist long after smoking has stopped.108 Systemic
neutrophil counts generally decrease within weeks but activated alveolar
macrophages may be present even years after smoking cessation.109 Unlike
nonsmokers, macrophage accumulations are found specifically in respiratory
bronchioles, even in young smokers, and BALF from smokers contains many fold
increases in macrophages compared to the numbers in BALF from nonsmokers.110
22
Besides releasing proteinases that might degrade the extracellular matrix of the
lung,111 alveolar macrophages in COPD make chemotactic factors that recruit other
inflammatory cells to the lungs. Likewise, structural cells of the lungs in COPD
produce proteinases and chemotactic factors for inflammatory cells.112 Expression
of interleukin-8 (IL-8), macrophage inflammatory protein-1α (MIP-1α), and
monocyte chemoattractant protein-1 (MCP-1), for example, are upregulated in
bronchiolar epithelium in COPD.113 Peptides of elastin are chemotactic for
inflammatory cells and may act as epitopes for T-cell responses.114In mice,
genetically induced overexpression of cytokines, such as IL-13 or γ interferon by
lung cells leads to emphysema via a robust innate immune response, with
inflammatory cell proteinases being integral in emphysema pathogenesis.115
Acquired Immune Responses
Cellular and humoral immunity may also be involved in emphysema pathogenesis
or the continued progression after smoking cessation. CD4+ and CD8+ T cells and
B cells accumulate in alveolar and airway tissue in COPD and form bronchus-
associated lymphoid tissue (BALT) in the walls of small airways.104 The increasing
BALT presence in small airways correlates with severity of GOLD stage.104 In
mice, exposure to antibodies directed at endothelial cells alone elicits alveolar septal
cell destruction and emphysema. Speculation about antigens for immunologically
driven emphysema in patients include microbial pathogens, peptides altered by
tobacco smoke, and peptides released from lung extracellular matrix.116 Difficulties
in distinguishing cellular and humoral responses to microbial colonization of
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advanced airway disease in COPD from pathologic self-directed immune responses
will require further study,117 but more targeted immune suppression in treating
advanced COPD has not yet shown benefit.118 Intrinsic in this issue is the
accelerated emphysema in smokers with HIV, but that may be complicated by direct
virus infection inducing macrophage alterations, rather than suppression of acquired
immune responses.
PROTEINASE–ANTIPROTEINASE IMBALANCE
The discovery in the 1960s of α1-AT deficiency associated early-onset emphysema
and the production of emphysema in experimental animal models with elastolytic
enzymes have promoted the imbalance of proteinases relative to their inhibitors as a
key factor in emphysema development.119 Although additional mechanisms, like
apoptosis and oxidant stress, have been uncovered in recent years, the importance of
proteinase excess continues to prevail as an important mechanism in emphysema
development. Proteinases of several biochemical classes, and different specific
inhibitors, are implicated in the pathogenesis of emphysema. Serine proteinases,
especially neutrophil elastase, and several matrix metalloproteinases, have been the
proteinases for which there are the most data. It is notable that both neutrophils,
which are the source of neutrophil elastase and MMP-12 from alveolar macrophages
are largely related to continued smoking. Progression after smoking cessation may
follow different pathways. As discussed in the genetics section many of these genes
have been implicated in candidate gene studies but not genome-wide association
studies .120 Although neutrophil elastase and its main inhibitor α1-AT have
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predominated the proteinase–antiproteinase imbalance hypothesis, MMPs appear
prominent in mouse models and in samples from smokers and individuals with
COPD. It is likely a combination of many local imbalances involving different
proteinases and antiproteinases contribute to the progressive lung destruction.
Several aspects of proteinases in COPD should be noted, as a straightforward
destructive mechanism only is likely an oversimplification. In addition to
destruction of lung elastin and other matrix components, proteinases process
cytokines and surface receptors involved in the inflammatory and immune
responses.121 Inflammatory cells may not be the exclusive sources of the proteinases
as structural cells also produce matrix-degrading proteinases.122 Even the apparently
simple emphysema model of placing elastases in the lungs of experimental animals
results in complex responses that can be altered by nonproteinase-related
mechanisms including stem cell and immunologic responses.123 It must also be
emphasized that little is known about proteinases in the pathogenesis of the small
airway pathology of COPD. Virtually all of the information about proteinases in
COPD pertains to emphysema pathogenesis despite clear evidence of small airway
obliteration in advanced disease.
OXIDANT–ANTIOXIDANT IMBALANCE
Reactive oxygen species in cigarette smoke or released by inflammatory cells and
structural cells of the lungs in response to smoke may lead to lung injury. Up to 20
mg of tar may be deposited in a smoker’s lung per cigarette smoked. This tar
contains more than 1017 stable, long-lived radicals per gram. The gas phase of
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tobacco smoke contains 1015 organic radicals per puff of smoke, although in
general these small oxygen- and carbon-centered species are more short-lived and
reactive than the radicals in the particulate phase. In addition, tobacco smoke
appears to “prime” neutrophils and alveolar macrophages to generate elevated
amounts of reactive oxygen species, such as hydrogen peroxide, hydroxyl radicals,
and superoxide radicals. The lung tissue of smokers contains significantly more iron
than that of nonsmokers,124 providing a catalyst for the production of hydroxyl
radicals from H2O2. This is of interest given the finding of an iron-binding protein
polymorphism in the genome wide association studies of smokers with COPD.
Smokers also demonstrate increased production of neutrophil myeloperoxidase,
which is capable of yielding oxidized halogens such as hypochlorous acid (HOCl).
Oxidants modify and inactivate proteins, such as protease inhibitors (α1-AT and
secretory leukoprotease inhibitor), and histone deacetylase 2 (HDAC2), which is
involved in glucocorticoid mediated anti-inflammatory responses. Oxidants can
affect lipids, DNA, and some specific end products, such as 4-hydroxy-2- nonenal
(4-HNE) and 8-hydroxy-2′-deoxyguanosine (8-OHdG), may be markers of
COPD.125 Oxidants can promote inflammation and proteinase expression, facilitate
proteinase-mediated extracellular matrix degradation by enhancing matrix molecule
susceptibility to proteolytic cleavage, and participate in nonenzymatic degradation
of matrix molecules like type I collagen. In experimental animals the combination
of cigarette smoke and elastase leads to greater emphysema than either insult alone,
suggesting that these insults do not elicit identical responses.126 Animal models of
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antioxidant deficiency result in increased susceptibility to both cigarette smoke and
direct elastase-induced disease.
APOPTOSIS AND SENESCENCE
Emphysematous human lung specimens demonstrate increased apoptotic and
senescent cells compared to healthy lung specimens.127 An early theory of
emphysema development was that alveolar vascular destruction preceded loss of
alveolar tissue. Consistent with this early theory, the blockade of vascular
endothelial growth factor (VEGF) signaling in alveolar endothelial cells or genetic
downregulation of VEGF production in alveolar epithelium produces apoptosis and
noninflammatory emphysema in rodents.128 In vitro, cigarette smoke induces
apoptosis of several lung cell types.129 An important feature of experimental models
of emphysema due to apoptosis is that there is minimal inflammation.130 Of interest,
the BICD1 gene polymorphism linked to emphysema encodes for a protein in the
apoptosis pathway. In contrast to the expanding body of information linking
emphysema to apoptosis, there is only scant information about apoptosis of the cells
of small airways in COPD. Much remains to be learned about apoptosis in the
context of COPD airway disease. Senescence of lung cells as a cause of emphysema
stems from the knowledge of alveolar loss with aging and animal models 131where
accelerated aging results in emphysematous changes. Lung fibroblasts isolated from
human lungs with COPD demonstrate increased markers of senescence and
senescent fibroblasts do not maintain the extracellular matrix.132 However, much of
the information regarding telomeres in human COPD relates to inflammatory cell
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telomere shortening, with telomere length being a biomarker of chronic lifelong
inflammatory excess present in individuals with COPD.133 Whether lung epithelial
cells are driven to an injury-related replicative senescence is unknown, but human
diseases of telomere deficiency and excess alveolar epithelial apoptosis tend to
result in pulmonary fibrosis and not COPD.134
MUCUS HYPERSECRETION
Airway mucus is a normal protective barrier that is constantly replenished and
cleared in health. Mucin glycoproteins, the main components of mucus, have a core
protein rich in serine and threonine, to which carbohydrates and cysteine residues
are attached. Mucus is secreted from submucosal glands and airway goblet cells. In
COPD there is hyperplasia of goblet cells and hypertrophy of glands with an
increase in the ratio of glandular mucus cells to serous cells. The changes in COPD
are associated with an alteration of the mucus proteins (MUCs) to favor a
predominance of MUC5B over the typical MUC5AC form, and an increase in the
MUC2 form, which is uncommon in normal lung mucus.135 Other alterations in the
mucus layer in COPD include greater acidity, less mucin glycosylation, and
decreased antimicrobial peptides. Mediators responsible for mucus hypersecretion
include proteinases, cytokines, oxidants, and epidermal growth factor receptor
(EGFR) ligands.136The negative charge of mucus glycoproteins results in
sequestration of proteases, volatile hydrocarbons and possibly preservation of the
hydration of the ciliated layer, resulting in protection of the underlying lung and
likely improved carcinogen clearance. However, the symptoms of mucus
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hypersecretion are common complaints in individuals with COPD; quantity and
location of mucus may be particularly important in symptomatic COPD.
Determining the relationship between chronic cough and sputum in patients with
COPD and the natural history of COPD has been elusive.137 Reports vary from
finding weak to strong correlations between cough and sputum production and
COPD progression, COPD exacerbations, and mortality.138 A relationship between
chronic mucus hypersecretion in small airways and adverse outcomes is plausible as
histological analysis of small airway pathology in COPD demonstrated that the
extent of small airway luminal obstruction by mucus correlated with the GOLD
stage and was inversely correlated with survival after lung volume reduction
surgery.139 Whether the mucus glycoproteins are a beneficial factor that mark the
degree of inflammation (e.g., a biomarker of inflammation) or are themselves a
pathologic factor in the severity of symptoms or progression of disease is an
important question, as treatment of mucus hypersecretion without adequate
suppression of the inciting inflammation may result in undesired consequences140
CLINICAL FEATURES:
The characteristic symptoms of COPD are chronic and progressive dyspnea, cough,
and sputum production that can be variable from day-to-day 141. Chronic cough and
sputum production may precede the development of airflow limitation by many
years. Individuals, particularly those exposed to COPD risk factors, who present
with these symptoms should be examined to search for an underlying cause(s) and
appropriate interventions taken. Conversely, significant airflow limitation may
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develop without chronic cough and sputum production. Although COPD is defined
on the basis of airflow limitation, in practice the decision to seek medical help is
usually determined by the impact of a symptom on a patient’s daily life. A person
may seek medical attention either because of chronic symptoms or because of a first
exacerbation.
Dyspnea
Dyspnea, a cardinal symptom of COPD, is a major cause of disability and anxiety
associated with the disease. Typical COPD patients describe their dyspnea as a
sense of increased effort to breathe, heaviness, air hunger, or gasping142. However,
the terms used to describe dyspnea vary both by individual and by culture143.
Cough
Chronic cough, often the first symptom of COPD to develop144, is frequently
discounted by the patient as an expected consequence of smoking and/or
environmental exposures. Initially, the cough may be intermittent, but later is
present every day, often throughout the day. The chronic cough in COPD may be
unproductive. In some cases, significant airflow limitation may develop without the
presence of a cough.
Sputum production
COPD patients commonly raise small quantities of tenacious sputum after coughing
bouts. Regular production of sputum for 3 or more months in 2 consecutive years is
the epidemiological definition of chronic bronchitis145, but this is a somewhat
arbitrary definition that does not reflect the range of sputum production in COPD
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patients. Sputum production is often difficult to evaluate because patients may
swallow sputum rather than expectorate it, a habit subject to significant cultural and
gender variation. Patients producing large volumes of sputum may have underlying
bronchiectasis. The presence of purulent sputum reflects an increase in
inflammatory mediators, and its development may identify the onset of a bacterial
exacerbation146.
Wheezing and Chest Tightness
Wheezing and chest tightness are nonspecific symptoms that may vary between
days, and over the course of a single day. Audible wheeze may arise at a laryngeal
level and need not be accompanied by auscultatory abnormalities. Alternatively,
widespread inspiratory or expiratory wheezes can be present on listening to the
chest. Chest tightness often follows exertion, is poorly localized, is muscular in
character, and may arise from isometric contraction of the intercostal muscles. An
absence of wheezing or chest tightness does not exclude a diagnosis of COPD, nor
does the presence of these symptoms confirm a diagnosis of asthma.
Additional Features in Severe Disease
Fatigue, weight loss and anorexia are common problems in patients with severe and
very severe COPD147. They are prognostically important148 and can also be a sign of
other diseases (e.g., tuberculosis, lung cancer), and therefore should always be
investigated. Cough syncope occurs due to rapid increases in intrathoracic pressure
during prolonged attacks of coughing. Coughing spells may also cause rib fractures,
which are sometimes asymptomatic. Ankle swelling may be the only symptomatic
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pointer to the development of cor pulmonale.symptoms of depression and anxiety
merit specific enquiry in the clinical history because they are common in COPD149
and are associated with increased risk of exacerbations and poorer health status.
COMPLICATIONS
PNEUMOTHORAX
Pneumothorax may develop spontaneously in patients with COPD. Depending on
the degree of respiratory impairment, a pneumothorax may result in significant
dyspnea and even acute respiratory failure. Pneumothorax was treated similarly in
COPD as in other conditions, although patients with severe emphysema are at
increased risk for persistent air leaks, which may be difficult to treat.
GIANT BULLAE
Emphysema may present with large bullae that can occupy a good portion of the
hemithorax. Surgical treatment can be considered if compression of adjacent lung
tissue is significant and surgical intervention is expected to improve pulmonary
mechanics.150 Bullae may also become infected. An increased frequency of lung
cancer has been reported in association with large bullae, seen either as a mass
within the bulla or a thickening of the wall.
PNEUMONIA
Pneumonia is not uncommon in patients with COPD and should be in the
differential diagnosis for any patient with COPD presenting with increased dyspnea,
cough, sputum production, and/or fever, which can make it difficult to distinguish
from an acute exacerbation of COPD without a chest radiograph. While COPD is
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believed to increase the risk for pneumonia, epidemiologic data are limited.151
Inhaled corticosteroids (ICS), which are frequently employed in the treatment of
COPD because they reduce the frequency of COPD exacerbations, have been
associated with an increased risk for pneumonia, particularly in older patients with
COPD. All patients with COPD should be immunized against pneumococcus.
COR PULMONALE
Cor pulmonale refers to altered structure or function of the right ventricle resulting
from pulmonary hypertension (PH) associated with chronic lung disease. The
prevalence of cor pulmonale in COPD is not known with certainty but reported
prevalence ranges from 1% to more than 70% depending on the patient population
examined and the methodology employed for defining PH.152 When PH develops in
the setting of COPD, the severity tends to be modest; severe resting PH due to
COPD is relatively uncommon. Signs and symptoms of cor pulmonale include an
increase in dyspnea, chest pain, and syncope. Severe cor pulmonale often presents
with an increase in lower extremity edema, which should prompt further
investigation. Other physical examination findings include right ventricular heave,
prominent pulmonic component to the second heart sound, tricuspid regurgitation
murmur, and a right-sided S4. Electrocardiographic findings may include right axis
deviation, evidence of right ventricular hypertrophy, and right bundle-branch block,
but overall these findings are rather insensitive for diagnosis of PH.
Echocardiography can be diagnostically helpful although not infrequently images
are limited in patients with parenchymal lung disease and hyperinflation. In
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addition, the correlation between echocardiogram and right heart catheterization is
imperfect; sensitivity tends to be better than specificity, suggesting that normal
results on echocardiogram can help exclude significant cor pulmonale. Right heart
catheterization remains the “gold standard” for diagnosis. PH in COPD is associated
with worse outcomes, including increased risk for hospitalization and worse
survival. There are few data to support the use of vasodilators for treatment of PH in
COPD. Oxygen is the only therapy for PH in COPD and also improves mortality in
appropriately selected patients.152
SLEEP DISORDERS
As many as 40% of COPD patients report sleep difficulties such as poor sleep
quality or difficulties initiating or maintaining sleep.153 The combination of COPD
and obstructive sleep apnea (OSA) is commonly referred to as “overlap syndrome.”
The frequency of OSA in the COPD patient population has been estimated to be
approximately 16%, which is roughly similar to that of the general population,
although the consequences of OSA in patients with COPD are more significant.
Compared to patients with OSA alone or with COPD alone, patients with COPD
with OSA tend to have more severe nocturnal hypercapnia and hypoxemia as well
as increased risk for PH. OSA in COPD is also associated with poorer quality of
life, frequent exacerbations, and increased mortality. Diagnosis of OSA in COPD is
important because continuous positive airway pressure therapy for patients with
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overlap syndrome has been associated with both decreased risk of death and
decreased incidence of severe exacerbations
Key Indicators for Considering a Diagnosis of COPD.
Dyspnea
Chronic cough
Chronic sputum production
History of exposure to risk factors
Family history of COPD
DIAGNOSIS AND EVALUATION:
Assessment of Symptoms
In the past, COPD was viewed as a disease largely characterized by breathlessness.
A simple measure of breathlessness such as the Modified British Medical Research
Council (mMRC) Questionnaire was considered adequate for assessment of
symptoms, as the mMRC relates well to other measures of health status154 and
predicts future mortality risk155. However, it is now recognized that COPD has
multiple symptomatic effects. For this reason, a comprehensive symptom
assessment is recommended rather than just a measure of breathlessness.
COPD Assessment Test (CAT)
The COPD Assessment Test is an 8-item unidimensional measure of health status
impairment in COPD156. It was developed to be applicable worldwide and validated
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translations are available in a wide range of languages. The score ranges from 0-40,
and has been extensively documented in numerous publications157
Spirometry
Pulmonary function testing and, in particular, spirometry is essential to establish a
diagnosis of COPD. While symptoms suggest a diagnosis, unfortunately their
predictive value for a diagnosis of COPD is poor. Several screening tools have been
developed, including questionnaires Spirometry can be performed in the physician’s
office and should be done in any patient with symptoms (e.g., cough, sputum,
dyspnea) and risk factors. When performing spirometry, a subject exhales forcefully
and the FEV1 is compared against the total air exhaled, which is the FVC. COPD is
defined by a reduction in the FEV1/FVC ratio. The degree of FEV1 reduction
defines the severity of airflow obstruction. The flow volume loop in COPD typically
has a concave appearance and the volume time curve demonstrates a prolonged
expiratory time
The ATS and the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
recommend that post-bronchodilator values be used to help distinguish COPD from
asthma. GOLD recommends an FEV1/FVC less than 0.70 as the threshold for
presence of airflow obstruction.158 Rather than using the fixed ratio, the ATS/ERS
recommends using the fifth percentile for the lower limit of normal. In general, the
fixed ratio approach leads to overdiagnosis in older subjects because the FEV1/FVC
ratio declines with age, even in healthy individuals.159
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COPD severity has typically been graded based on FEV1% predicted, which is part
of the GOLD
GOLD Classification of Severity of Airflow
In Patients with FEV1/FVC < 0.70
GOLD 1: mild FEV1 ≥ 80% predicted
GOLD 2: moderate 50% ≤ FEV1 < 80% predicted
GOLD 3: severe 30% ≤ FEV1 < 50% predicted
GOLD 4: very severe FEV1 < 30% predicted
Exercise Testing
The 6-minute walk test (6MWT) is probably the most frequently employed exercise
test in COPD. The distance that a patient can walk in 6 minutes is termed the 6-
minute walk distance (6MWD). An advantage of the 6MWT is that it requires little
training to administer and no specialized equipment. While a 6MWT is not required
to make a diagnosis of COPD, it allows the clinician to assess oxygenation during
ambulation and the potential need for supplemental oxygen. 6MWD is also
frequently employed during lung transplant evaluation to gauge functional status
and prognosis. 6MWD has been demonstrated to relate to mortality in COPD and is
a component of the BODE mortality index.160 While there is good correlation
between 6MWD and peak oxygen uptake in end-stage lung disease,161 the 6MWT
should be considered complementary to the CPET. Most patients do not achieve
maximal exercise capacity during the 6MWT and consequently the 6MWD may
better reflect functional exercise capacity. The 6MWD also correlates better with
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quality of life measures; therapeutic interventions resulting in changes in 6MWD
also correlate with improvements in dyspnea.162 Some form of exercise testing is
typically employed before and after pulmonary rehabilitation to assess
improvement. CPET is also a necessary part of evaluation for lung volume
reduction surgery (LVRS), because LVRS may provide a survival benefit for those
with a low work rate after pulmonary rehabilitation.
IMAGING
Chest radiography and computed tomography (CT) are the two imaging modalities
most commonly used in COPD. While not required to diagnose COPD, imaging can
be helpful to rule out concomitant processes. Chest radiographs are frequently
obtained to investigate dyspnea or hemoptysis or to look for pneumonia, heart
failure, lung cancer, or pneumothorax. Chest radiography is not particularly
sensitive or specific for the diagnosis of COPD. There are certain features, however,
that are often seen in COPD. Radiolucency, diaphragmatic flattening, and increased
retrosternal airspace on the lateral radiograph may be seen when hyperinflation is
present.
Chest CT allows better detection and quantification of emphysema than does
traditional chest radiography. Areas of low attenuation are a marker of emphysema;
thickened airways indicative of bronchial thickening may also be seen. If expiratory
views are obtained, areas of air trapping indicative of small airway obstruction and
emphysema may also be seen. CT is not indicated in the routine diagnosis or
evaluation of COPD, but can be helpful when evaluating individuals with very
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severe COPD. CT imaging is required to quantify emphysema extent and
distribution for the purposes of LVRS. Individuals with very severe COPD
undergoing transplant evaluation typically require a chest CT to rule out the
presence of lung cancer and aid with surgical planning. CT imaging is also helpful
when the clinician is concerned about a concomitant process such as interstitial lung
disease which may be suggested on pulmonary function testing or when hemoptysis
or other unexplained changes in symptoms develop.
LABORATORY TESTING
Arterial Blood Gases
Arterial blood gases (ABGs) are not indicated as part of the routine evaluation for
patients with mild to moderate COPD. However, ABGs can be helpful to assess
hypoxemia and to provide information regarding hypercapnia, particularly in
individuals with more severe disease or during an acute exacerbation.
Erythrocytosis
Elevated hemoglobin may be seen in COPD, particularly in the presence of chronic
hypoxemia. A hemoglobin value is also helpful in the evaluation of dyspnea
because anemia is a common cause of dyspnea that should be ruled out. In addition,
DLCO is most accurate when adjusted for hemoglobin.
Serum Bicarbonate
An elevated serum bicarbonate can suggest chronic hypercapnia; in the setting of
hypercapnia, serum bicarbonate is increased due to compensatory metabolic
alkalosis.
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Alpha1-Antitrypsin Deficiency
The ATS guidelines recommend testing for A1AT deficiency for all individuals
with persistent airflow obstruction.163 A1AT is a protease that inactivates neutrophil
elastase. Clinical features suggestive of A1AT deficiency include emphysema at a
young age, emphysema in an individual with minimal or no smoking history, lower
lobe predominant emphysema, and a family history of emphysema. However,
A1AT deficiency can also be present in patients with more typical COPD
presentations. In individuals with established COPD, diagnostic testing is
recommended. The chest radiograph and CT show the predominantly lower lobe
distribution of emphysema, consistent with a panacinar pattern  and different from
the more common centriacinar pattern
Sputum.
Sputum evaluation is not indicated in the routine diagnosis and care of the COPD
patient. In patients with stable disease, sputum examination typically reveals a
predominance of macrophages and few bacteria. During exacerbations, the number
of organisms on Gram stain typically increases. The most common pathogens
identified on sputum culture include Haemophilus influenzae, Moraxella catarrhalis
and Streptococcus pneumoniae. However, the relationship between identification of
organisms in sputum and pathogenic contribution to acute exacerbations has been
questioned because longitudinal studies have suggested that the incidence of
bacterial isolation from sputum during an acute exacerbation of COPD was no
different from that of the stable state,164 although bacteria identified in sputum
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during stable COPD have been associated with a greater exacerbation frequency and
lung function decline. In general, exacerbations typically respond to empirical
treatment.
GOLD COMBINED ASSESSMENT PROPOSAL
GOLD has recently proposed a new multidimensional system for the assessment
and management of COPD
The groups can be summarized as follows:
Patient Group A – Low Risk, Less Symptoms
Typically GOLD 1 or GOLD 2 (Mild or Moderate airflow limitation); and/or 0-1
exacerbation per year and no hospitalization for exacerbation; and CAT score < 10
or mMRC grade 0-1
Patient Group B – Low Risk, More Symptoms
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Typically GOLD 1 or GOLD 2 (Mild or Moderate airflow limitation); and/or 0-1
exacerbation per year and no hospitalization for exacerbation; and CAT score ≥ 10
or mMRC grade ≥ 2
Patient Group C – High Risk, Less Symptoms
Typically GOLD 3 or GOLD 4 (Severe or Very Severe airflow limitation); and/or ≥
2 exacerbations per year or ≥ 1 with hospitalization for exacerbation; and CAT score
< 10 or mMRC grade 0-1
Patient Group D – High Risk, More Symptoms
Typically GOLD 3 or GOLD 4 (Severe or Very Severe airflow limitation); and/or ≥
2 exacerbations per year or ≥ 1 with hospitalization for exacerbation; and CAT score
≥ 10 or mMRC grade ≥ 2
DIFFERENTIAL DIAGNOSIS
 Asthma
 Congestive Heart Failure.
 Bronchiectasis
 Tuberculosis
 Obliterative Bronchiolitis
 Diffuse Panbronchiolitis
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MANAGEMENT
GENERAL PRINCIPLES OF TREATMENT
Goals of treatment of COPD are:
 To reduce symptoms- relief of dyspnea, improved exercise tolerance, and
improved health status
 To reduce risk by preventing and treating exacerbations
 Preventing disease progression
Rreducing mortality
 To minimize the adverse effects of medications.
Reduction of Risk Factors
In the case of COPD, risk reduction refers to interventions that may decrease the
likelihood of developing the disease, slow disease progression, decrease
exacerbations, and reduce mortality. Although our knowledge of the factors that
contribute to each of these is limited, there are substantial data on some factors that
contribute to each of these.
Smoking Cessation
Throughout the developed world, cigarette smoking is the most important risk factor
for the development of COPD. Public health and educational programs aimed at
discouraging people from smoking and efforts to help active smokers stop are
probably the most important intervention for COPD. National Institutes of Health–
sponsored Lung Health Study demonstrated that in smokers with COPD, smoking
cessation reduced the rate of decline in lung function, whereas inhaled
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bronchodilator did not.165 In a 14.5-year follow-up to the Lung Health Study,
Anthonisen and colleagues reported that the lung-function benefit continued for
persistent quitters; there was also a mortality (all cause) benefit for those who
maintained abstinence. Perhaps more important, even those whose smoking
cessation was intermittent experienced a benefit compared with continued
smokers.166 Smoking cessation education and support should be offered to every
patient with COPD, at every visit.
Biomass Fuel
In the developing world, cigarette smoke is less of an issue than is exposure to
biomass fuel, used for cooking and heating. The exposure is particularly great for
women and their young children, who may spend the greater part of each day
indoors with an unvented fire, fueled by wood, dung, or kerosene. Such exposure
has been associated with chronic bronchitis and COPD.167 Guarnieri and colleagues
showed that something as simple as a vented stove can decrease gene expression for
markers of inflammation in sputum.
Environmental Controls
Allergens and air pollutants may have an impact on COPD. In addition, a growing
body of evidence suggests that long term exposure to even low levels of air
pollution increase the risk for COPD.168 Also, people with COPD who also have
allergic disease have higher levels of respiratory symptoms and are at higher risk for
COPD exacerbations. As a consequence, people with COPD should avoid noxious
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exposures, heed air quality warnings, and be cautious of ongoing occupational
exposures.
Prevention of Respiratory Infections
A significant proportion of COPD exacerbations are triggered by respiratory
infections. Although there are some data to suggest that patients with COPD are
more susceptible to respiratory infections because of impaired mucociliary
clearance, a more important issue is that those with COPD are more susceptible to
the consequences of respiratory tract infections. As a general rule, every patient with
COPD should be immunized annually against influenza, which is effective at
reducing the incidence of influenza regardless of the severity of COPD, and has
been demonstrated to reduce mortality in older adults.169 In addition all should be
vaccinated against S. pneumoniae.  More recently, Chronic antibiotics for
prophylaxis trials with erythromycin and moxifloxacin have demonstrated a
reduction in exacerbations. There has been a particular interest in macrolide
antibiotics, because of their demonstrated value in diffuse panbronchiolitis and in
cystic fibrosis, and because they may have anti-inflammatory as well as
antimicrobial properties.
Prevention of Exacerbations
Exacerbations of COPD are sentinel events and are closely associated with disease
progression. Increasing severity of COPD is associated with increased exacerbations
and need for hospitalization, but for every stage of severity, severe exacerbations are
associated with increases in short-term and long-term all-cause mortality.170
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Exacerbations have an independent negative effect on prognosis, and mortality
increases with the frequency of hospitalizations.  Although supporting data are
lacking, the hope is that, by preventing exacerbations, lung function may be
preserved and deterioration prevented. ICS, long-acting β-agonists, long-acting
muscarinic antagonists, and macrolide antibiotics have all been shown to reduce
exacerbations. Unfortunately, even patients taking these medications may still
experience as many as 1.4 exacerbations per year.
TREATMENT RECOMMENDATIONS :
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Bronchodilators
Medications that increase the FEV1 or change other spirometric variables, usually
by altering airway smooth muscle tone, are termed bronchodilators.
Bronchodilators are recommended for all patients with COPD. Pharmaceutical
classes of bronchodilators include β-agonists, antimuscarinics (anticholinergics),
and methylxanthines. Bronchodilator medications are central to symptom
management in COPD.
• Inhaled therapy is preferred.
• The choice between beta2-agonist, anticholinergic, theophylline, or combination
therapy depends on availability and individual patient response in terms of symptom
relief and side effects.
• Bronchodilators are prescribed on an as-needed or on a regular basis to prevent or
reduce symptoms.
• Long-acting inhaled bronchodilators are convenient and more effective at
producing maintained symptom relief than short-acting bronchodilators.
• Combining bronchodilators of different pharmacological classes may improve
efficacy and decrease the risk of side effects compared to increasing the dose of a
single bronchodilator.
Even patients who do not respond to bronchodilator testing in the pulmonary
function laboratory should be given a clinical trial of bronchodilators. Although the
increase in FEV1 may be modest, it may be sufficient to improve lung emptying
and, by this mechanism, reduce dynamic hyperinflation.171 In multiple studies,
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bronchodilators have been shown to reduce dyspnea and increase exercise tolerance
in patients with chronic stable COPD.172
β-Adrenergic Agonists
These medications bind directly to β-receptors located on airway smooth muscle
and dilate the airway. Less prominent effects include increased ciliary beat
frequency that promotes mucus transport along the mucociliary escalator and
improved respiratory muscle endurance.173 β-agonists are available in both short-
acting and longacting preparations, and can be administered by inhalation, orally,
subcutaneously, or intravenously. For treatment of COPD, β-agonists should only be
given as inhaled aerosols, because the other routes are associated with an
unacceptably high risk of systemic adverse effects.
Short-acting beta agonists (SABAs) include albuterol (salbutamol), levalbuterol,
terbutaline, and fenoterol. Albuterol is a racemic mixture of both (R)- and (S)-
enantiomers of albuterol; levalbuterol is the (R)-enantiomer alone. The (R)-
enantiomer is thought to be responsible for bronchodilation while the (S)-
enantiomer is believed to cause tremor, tachycardia, and perhaps airway
inflammation. Thus, levalbuterol would be expected to be better tolerated than
albuterol. In fact, for most patients with stable COPD who use their short-acting β-
agonist for symptom management, the added advantage of levalbuterol over
albuterol is probably not significant.174 Albuterol is also available in combination
with ipratropium (a muscarinic antagonist) Short-acting β-agonists for inhalation are
available in solution for administration by nebulizer, as well as by metered-dose
48
inhaler and dry powder inhaler (DPI). The combination of albuterol and ipratropium
is available in a soft mist inhaler. Many studies have shown that metered dose
inhalers, DPIs, and soft mist inhalers are as effective as nebulizers in patients who
are able to use the devices properly. Unfortunately, the proper technique for using
different devices is not the same, and patients need detailed instruction and periodic
assessment of their technique. In addition, DPIs require a much higher inspiratory
flow than do metered-dose inhalers and some patients with moderate-tosevere
COPD may not be able to generate adequate flows. For these individuals and for
those whose medical or mental status makes coordinated breathing efforts difficult,
nebulized β-agonists may be preferable.175
The major advantage of short-acting β-agonists is their rapid onset of action, within
5 to 15 minutes after inhalation. Their effects last for 2 to 6 hours. Most patients
with COPD demonstrate a modest improvement in FEV1, and many studies and
meta-analyses support their use for COPD.176 The combination of albuterol and
ipratropium results in greater and more sustained improvement in lung function than
either drug alone.177 When used at the recommended doses, inhaled short-acting β-
agonists are thought to be safe.
The major adverse effects include tremor, anxiety, tachycardia, and hypokalemia.
Adverse effects are dose-dependent and are less common with inhaled compared
with systemic dosing, and when inhaler technique is optimized. Fortunately,
tachyphylaxis to the systemic side effects of β-agonists is greater than tachyphylaxis
to the bronchodilator effect.
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Long-acting β-agonists (LABAs) typically produce bronchodilation that lasts for
12 hours or more. Salmeterol was the first LABA to be studied extensively. Its onset
of action is much slower than that of albuterol, on the order of 20 to 30 minutes.
Formoterol has a similar duration of action, but an onset of action that is nearly
identical to albuterol.
Both salmeterol and formoterol must be taken twice daily. Arformoterol is the (R)-
enantiomer of formoterol. Indicaterol has a rapid onset and a duration of action of
nearly 24 hours, and thus requires only once daily dosing. The bronchodilator effect
of indicaterol is greater than that of salmeterol or formoterol. Vilanterol is another
LABA with a rapid onset of action and a duration of action of approximately 24
hours. It is not used as monotherapy, but  used in combination with the ICS
fluticasone. Many studies have demonstrated a benefit of LABAs in patients with
stable COPD.178 Salmeterol and formoterol significantly improve lung function,
dyspnea, quality of life, and the rate of exacerbations.179 Salmeterol has been shown
to reduce hospitalizations. Indicaterol improves dyspnea and health status, and
reduces exacerbations. The adverse effects reported with LABAs are similar to
those described for short-acting β-agonists. Monotherapy with an LABA appears to
be both safe and efficacious. LABAs are frequently combined with an ICS in the
same inhaler, and currently available preparations include salmeterol/fluticasone,
formoterol/budesonide, formoterol/mometasone, and vilanterol/fluticasone. Many
studies have shown that combination therapy is often more effective than either
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agent alone, and various guidelines provide recommendations for how and when to
escalate treatment beyond short-acting bronchodilators.
Antimuscarinics
Antimuscarinics, also known as anticholinergics or muscarinic antagonists, block
the effects of acetylcholine on M3 muscarinic receptors on airway smooth muscle.
The newer quaternary amines such as ipratropium and glycopyrrolate, as well as
tiotropium and aclidinium, are better tolerated because they do not cross the blood-
brain barrier. In addition, both tiotropium and aclidinium have pharmacokinetic
selectivity for the M3 receptor and dissociate more rapidly from M2 receptors,
which are found on cholinergic nerve terminals and inhibit acetylcholine release.
Thus, the relative lack of M2 binding by these muscarinic antagonists may allow
acetylcholine to bind to M2 receptors, thereby inhibiting further acetylcholine
release and reducing bronchoconstriction.
Short-acting muscarinic antagonists (SAMAs) include ipratropium and
oxitropium. They increase FEV1 with an onset of action of 10 to 15 minutes and a
duration of action of 4 to 6 hours. Ipratropium improves lung function, increases
exercise capacity, decreases dyspnea, and decreases cough.180 The magnitude of
bronchodilation with ipratropium is comparable to that seen with albuterol but,
when used in combination, their effects are additive and the duration is longer.
Long-acting muscarinic antagonists (LAMAs) include tiotropium and aclidinium,
which are slower in onset than ipratropium, but last longer, with bronchodilation
lasting at least 12 hours after aclidinium216 and more than 24 hours after
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tiotropium. Tiotropium decreases symptoms, improves health status, and reduces
exacerbations by 20% to 25%181and hospitalizations. It appears to improve the
effectiveness of pulmonary rehabilitation, perhaps by decreasing  dynamic
hyperinflation. In general, both short- and long-acting muscarinic antagonists have
good safety profiles.
The most common side effects are dry mouth and urinary retention. Medication that
contacts the eye, either by hand contact or by aerosolization, can cause blurred
vision and can precipitate glaucoma. A  metaanalysis of ipratropium and tiotropium
in COPD182 suggested that anticholinergic therapy was associated with an increased
risk of cardiovascular death, myocardial infarction, and stroke
METHYLXANTHINES
Methylxanthines are a group of structurally related compounds that are widely used
in the treatment of patients with asthma, chronic obstructive pulmonary disease
(COPD) and chronic cor pulmonale. Their effect is a generalised reduction of
airway obstruction that decreases the overall resistance of the airways, improves
blood gas exchange and reduces the dyspnoea. It has been recognised that these
drugs may provide benefits above and beyond the usual bronchodilation.
Unfortunately, therapy with xanthines is generally associated with a number of
adverse events, affecting the cardiovascular system, the central nervous system and
the gastrointestinal system.
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Theophylline, also known as 1,3-dimethylxanthine, one of the three naturally
occurring methylated xanthine alkaloids
Mechanism of action Three distinct cellular actions of methylxanthines have been
defined—(a) Release of Ca2+ from sarcoplasmic reticulum, especially in skeletal
and cardiac muscle.
(b) Inhibition of phosphodiesterase (PDE) which degrades cyclic nucleotides
intracellularly. The concentration of cyclic nucleotides is increased.
Bronchodilatation, cardiac stimulation and vasodilatation occur when cAMP level
rises in the concerned cell. Several isoenzymes of the PDE superfamily exist in
different tissues. Theophylline is a subtype nonselective and weak PDE inhibitor,
but PDE4 inhibition is mainly responsible for bronchodilatation. However, some
selective PDE4 inhibitors like Cilomilast and Roflumilast have been disappointing
clinically in efficacy as well as side effects.
(c) Blockade of adenosine receptors: adenosine acts as a local mediator in CNS,
CVS and other organs—contracts smooth muscles, especially bronchial; dilates
cerebral blood vessels, depresses cardiac pacemaker and inhibits gastric secretion.
Methylxanthines produce opposite effects.
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Action (a) is exerted only at concentrations much higher than therapeutic plasma
concentrations of caffeine and theophylline (ranging from 5–20 μg/ml). Action (b)
and action (c) are exerted at concentrations in the therapeutic range and appear
to contribute to bronchodilatation. Raised cAMP levels in inflammatory cells may
attenuate mediator release and promote eosinophil apoptosis adding to the
therapeutic effect of theophylline in asthma.
Adenosine A1 receptor antagonism is considered responsible for cardiac
arrhythmias and seizures occurring in theophylline toxicity. Recent evidence
suggests that low concentations of theophylline ehnace histone deacetylation in
airway inflammatory cells, suppressing proinflammatory gene transcription. Thus,
even sub-bronchodilator doses of theophylline may exert some beneficial effect in
asthma.
Pharmacokinetics
Theophylline is well absorbed orally; rectal absorption from suppositories is erratic.
It is distributed in all tissues—crosses placenta and is secreted in milk, (V 0.5 l/kg),
50% plasma protein bound and extensively metabolized in liver by demethylation
and oxidation primarily by CYP1A2. Only 10% is excreted unchanged in urine. Its
elimination rate varies considerably with age. At therapeutic concentrations, the t½
in adults is 7–12 hours. Children eliminate it much faster (t½ 3–5 hours) and elderly
more slowly. In premature infants also the t½ is prolonged (24–36 hours). There are
marked interindividual variations in plasma concentrations attained with the same
dose. Theophylline metabolizing enzymes are saturable, t½ is prolonged with higher
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doses (to as much as 60 hours) as kinetics changes from first to zero order. Plasma
concentrations, therefore, increase disproportionately with dose. Factors which need
dose reduction are— age> 60 yr (× 0.6), CHF (× 0.6), pneumonia (×0.4), liver
failure (× 0.2–0.4).
Serum Level Therapeutic Effect
<5 μg/ml No effect
10-20 μg/ml Therapeutic range
> 20 μg/ml Nausea
> 30 μg/ml Cardiac arrhythmias
40-45 μg/ml Seizures
Adverse effects
Theophylline has a narrow margin of safety. Dose-dependent toxicity starts from
the upper part of therapeutic concentration range .Adverse effects are primarily
referable to the g.i.t., CNS and CVS. Headache, nervousness and nausea are early
symptoms. Children are more liable to develop CNS toxicityThe irritant property of
theophylline is reflected in gastric pain (with oral), rectal inflammation (with
suppositories) and pain at site of i.m. injection. Rapid i.v. injection causes precordial
pain, syncope and even sudden death—due to marked fall in BP, ventricular
arrhythmias or asystole.
Interactions
1. Agents which enhance theophylline metabolism primarily by inducing CYP1A2
lower its plasma level: dose has to be increased by the factor given in parenthesis.
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Smoking (1.6), phenytoin (1.5), rifampicin (1.5),phenobarbitone (1.2), charcoal
broiled meat meal(1.3).
2. Drugs which inhibit theophylline metabolism and increase its plasma level are—
erythromycin, ciprofloxacin, cimetidine, oral contraceptives, allopurinol; dose
should be reduced to 2/3.
3. Theophylline enhances the effects of—furosemide, sympathomimetics, digitalis,
oral anticoagulants,hypoglycaemics.
4. Theophylline decreases the effects of—phenytoin,lithium.
5. Aminophylline injection should not be mixed in the same infusion bottle/syringe
with—ascorbic acid, chlorpromazine, promethazine, morphine, pethidine,
phenytoin, phenobarbitone, insulin,penicillin G, tetracyclines, erythromycin.
Preparations and dose
(i) Theophylline (Anhydrous) Poorly water soluble,cannot be injected. 100–300 mg
TDS (15 mg/kg/day)
Only sustained release (SR) tab./caps. are used, because fast release tabs. produce
high peak and low trough plasma concentrations.Because solubility of theophylline
is low, a number of soluble complexes and salts have been prepared, particularly for
parenteral use.
(ii) Aminophylline (Theophylline-ethylenediamine; 85%theophylline) water
soluble, can be injected i.v. but not i.m. or s.c.—highly irritating. 250–500 mg oral
or slow i.v. injection; children 7.5 mg/kg i.v.; AMINOPHYLLINE 100 mg tab, 250
mg/10 ml inj.
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(iii) Hydroxyethyl theophylline (Etophylline, 80% theophylline) water soluble; can
be injected i.v. and i.m.(but not s.c.), less irritating; 250 mg oral/i.m./i.v.;
DERIPHYLLIN 100 mg tab., 300 mg SR tab., 220 mg/2 ml inj.
(iv) Choline theophyllinate (Oxtriphylline; 64%theophylline) 250–500 mg oral,
CHOLIPHYLLINE 125 mgcap., 125 mg/5 ml elixir.
(v) Theophylline ethanolate of piperazine 250–500 mg
oral or i.v.; CADIPHYLLATE 80 mg/5 ml elixir,
ETOPHYLATE 125 mg/5 ml syrup.
Doxophylline
Doxofylline 7- (1, 3 dioxolane-2-yl methyl) is a newer xanthine derivative which
differs from theophylline in containing the diosalane group at position 7.
Mechanism of action :
Inhibits  the phosphodiesterase enzymes, but decreased affinities towards the
adenosine A1 and A2 receptors, which has been claimed as a reason for its better
safety profile
Doxofylline does not antagonize calcium channels, nor does it interfere with the
influx of calcium into the cells, which probably reduces the cardiac side effects.
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Moreover, it does not affect sleep rhythm, gastric secretions, heart rate and rhythm
and CNS functioning.
Pharmacokinetics :
Oral administration
Peak plasma levels were reached after 1 hour. Oral Bioavailability is 62.6%.Plasma
protein binding is 48%.completely metabolized in the liver. Hydroxyl ethyl
theophylline is the detectable metabolite. Around 4% is excreted unchanged in
urine.
Doxofylline reaches steady state in about 4 days after repeated administrations.The
elimination half life is 8-10 hrs allowing twice daily administration.
ADVERSE EFFECTS:
Nausea, vomiting, epigastric pain, cephalalgia, irritability, insomnia, tachycardia,
extrasystole, tachypnea, and occasionally hyperglycemia and albuminuria, may
occur. If a potential oral overdose is established, the patient may present with severe
arrhythmias and seizure; these symptoms could be the first sign of intoxication.
SPECIAL PRECAUTIONS
The half-life of xanthine derivatives is influenced by a number of known variables.
It may be prolonged in patients with liver disease, in patients with congestive heart
failure, in those affected with chronic obstructive lung disease or concomitant
infections, and in those patients taking certain other drugs (erythromycin,
troleandomycin, lincomycin, and other antibiotics of the same group, allopurinol,
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cimetidine, propranolol, and anti-flu vaccine). In these cases, a lower dose of
Doxofylline may be needed. Phenytoins, other anti-convulsants and smoking may
cause an increase in clearance with a shorter mean half-life: in these cases higher
doses of Doxofylline may be needed. Use with caution in patients with hypoxemia,
hyperthyroidism, liver disease, renal disease, in those with history of peptic ulcer
and in elderly.Frequently, patients with congestive heart failure have markedly
prolonged drug serum levels following discontinuation of the drug.
Use in Pregnancy and Lactation
Animal reproduction studies indicate that Doxofylline does not cause fetal harm
when administered to pregnant animals nor can affect reproduction capacity.
However, since there is limited experience in humans during pregnancy, xanthines
should be given to a pregnant woman only if clearly needed. Doxofylline is
contraindicated in nursing mothers.
DRUG INTERACTIONS
Doxofylline should not be administered together with other xanthine derivatives,
including beverages and foods containing caffeine. Toxic synergism with ephedrine
has been documented for xanthines.
Concomitant therapy with erythromycin, troleandomycin, lincomycin, clindamycin,
allopurinol, cimetidine, propranolol and anti-flu vaccine may decrease the hepatic
clearance of xanthines causing an increase in blood levels.
Dosage:
Adult Dose: 400 mg OD or BD
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children 12 mg/kg/day
Phosphodiesterase-4 Inhibitors
Phosphodiesterase-4 (PDE-4) inhibitors act by blocking the breakdown of cyclic
adenosine monophosphate. By this mechanism, they decrease airway inflammation;
they have no direct bronchodilator activity. Roflumilast is an oral PDE-4 inhibitor
that has been approved for patients with chronic bronchitis and a history of
exacerbations. In a meta-analysis of 23 randomized trials, the PDE-4 inhibitors
reduced exacerbations and produced a modest increase in FEV1 .183 When
roflumilast was added to salmeterol or tiotropium, the prebronchodilator FEV1
increased. Because its effect on exacerbations is much greater than its effect on
airway function, guidelines recommend that roflumilast be used in combination with
a long-acting bronchodilator.187 Use of PDE-4 inhibitors has been limited by the
side effects. The most common are nausea, anorexia, abdominal pain, diarrhea,
weight loss, sleep disturbances, and headache.184 Monitoring weight during
treatment is warranted.187
Corticosteroids
Inhaled Corticosteroids
Airway as well as systemic inflammation are critical components of the
pathogenesis of COPD.185 Therefore, corticosteroids, with their anti-inflammatory
effects, are an important intervention. ICS offer the additional advantage of
minimizing systemic exposure. ICS have been shown to improve symptoms, lung
function, and quality of life, and to reduce the frequency of COPD exacerbations,
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especially in patients with an FEV1 less than or equal to 60% of predicted. The
improvement in FEV1 achieved with ICS  is typically less than that observed with
bronchodilators.186 The reduction of exacerbations by ICS is more significant and is
comparable to that observed with LABAs or LAMAs Guidelines recommend that
ICS be used in combination with a long acting bronchodilator in subjects who are
prone to exacerbations, but that they not be used as monotherapy.187 In TORCH
trial where  6112 subjects with moderate-to severe COPD were randomly treated for
3 years with placebo, fluticasone, salmeterol, or the fluticasone/salmeterol
combination, Celli and colleagues reported that each active treatment arm reduced
the rate of decline in FEV1. Whether this benefit reflects the reduction in
exacerbations or a more direct effect on the airway, perhaps by decreasing
inflammation, is not known. ICS are relatively safe, especially in comparison to
systemic corticosteroids.
The most common adverse effects are oral candidiasis (thrush) and dysphonia, both
of which can be minimized by careful inhalation technique followed by rinsing the
mouth and gargling. Increased skin bruising is probably a manifestation of capillary
fragility. Reduced bone density has been reported after long-term treatment with
triamcinolone, but studies with budesonide and fluticasone have not found similar
results, perhaps because these patients with COPD had a high prevalence of
osteoporosis at baseline.188 Finally, although ICS clearly reduce the frequency of
exacerbations in COPD, they have been associated with an increased incidence of
pneumonia.
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Systemic Corticosteroids
With rare exceptions, the use of systemic corticosteroids should be reserved for the
treatment of exacerbations. In patients with stable disease, even when severe, the
risk of adverse effects is probably greater than the likelihood of benefit. Chronic use
of systemic corticosteroids is associated with increased mortality,189 which may
reflect corticosteroid effects or the underlying severity of the COPD. Occasionally,
in exacerbation-prone patients who require frequent courses of high dose systemic
corticosteroids, a very low daily dose of corticosteroids may protect against
exacerbations and thereby reduce the total annual steroid exposure. If this unusual
approach is followed, the lowest possible dose of corticosteroids should be used.
Spirometric stability may be useful in encouraging patients who are experiencing
nonpulmonary benefit that dose reduction is safe.
Combination Therapy
Patients who remain symptomatic after a period of treatment with a single long-
acting bronchodilator (either LABA or LAMA) may benefit from addition of a
second drug. Choices include either an ICS or a second long-acting bronchodilator
from the other pharmacologic class. ICS should probably be considered as the first
addition in patients with evidence of airway inflammation and those with frequent
exacerbations. There was no difference in exacerbations, but mortality was less in
the salmeterol/fluticasone group and health status was better. Pneumonia was more
frequent in the salmeterol/fluticasone group. Combinations of
formoterol/budesonide, formoterol/mometasone, and vilanterol/fluticasone have
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also been shown to improve some clinical outcomes. Finally, guidelines suggest
“triple inhaler therapy” for subjects whose symptoms are not controlled by any of
the combinations already described.187 This recommendation is in part empirical,
because each of the drugs or combinations have been shown to be effective.
However, several retrospective cohort studies have described decreased mortality,
and fewer exacerbations and hospitalizations with triple therapy.190,191 The only
prospective data comes from the UPLIFT trial, in which patients were randomized
to receive “usual care” with or without tiotropium. In those patients who were
already taking an ICS and a LABA , the addition of tiotropium significantly
improved lung function, reduced exacerbations, and improved health related quality
of life.192 Further studies are needed to define the role of triple-therapy
NONPHARMACOLOGIC TREATMENT
Mucus Clearance
In patients with mucus hypersecretion and airflow obstruction, it may be very
difficult to mobilize secretions. Maneuvers such as controlled cough and the huff
cough can be helpful. In the former, patients take a deep breath, hold their breath for
a few seconds, then cough two or three times with their mouth open and without
taking another breath. The sequence is then repeated several times. Huff coughing
involves one or two forced expirations starting at mid-lung volume and performed
with the glottis open. Mucus clearance can also be facilitated by having patients
breathe or cough through a device that generates high amplitude oscillations, or with
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an external percussive device. These maneuvers are considered safe, but data
supporting their use is limited.
Oxygen Therapy
The long-term administration of oxygen (> 15 hours per day) to patients with
chronic respiratory failure has been shown to increase survival in patients with
severe resting hypoxemia . Long-term oxygen therapy is indicated for patients who
have:
 SaO2 at or below 88%, with or without hypercapnia confirmed twice over a
three week period
 SaO2 of 88%, if there is evidence of pulmonary hypertension, peripheral
edema suggesting congestive cardiac failure, or polycythemia
A decision about the use of long-term oxygen should be based on the resting PaO2
or saturation values repeated twice over three weeks in the stable patient. Current
data do not support the use of ambulatory oxygen in patient populations that do not
meet the above criteria. Although air travel is safe for most patients with chronic
respiratory failure who are on long-term oxygen therapy, patients should ideally be
able to maintain an in-flight PaO2 of at least 6.7 kPa .This can be achieved in those
with moderate to severe hypoxemia at sea level by supplementary oxygen at 3
L/min by nasal cannulae or 31% by Venturi facemask361. Those with a resting
PaO2 at sea level > 9.3 kPa (70 mmHg) are likely to be safe to fly without
supplementary oxygen362,363, although it is important to emphasize that a resting
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PaO2 > 9.3 kPa (70 mmHg) at sea level does not exclude the development of severe
hypoxemia when travelling by air.
Exercise
Exercise training to improve cardiorespiratory function may be helpful; the type of
exercise does not appear to be important and aerobic exercise or upper limb
exercises are equally effective. Respiratory muscle training using resistive
inspiratory loading may reduce breathlessness, but a meta-analysis of controlled
studies of respiratory muscle training alone has provided no evidence of overall
benefit.193 Controlled breathing techniques, such as pursed-lip breathing and
diaphragmatic breathing, result in reduced dyspnea, particularly in patients with
hyperventilation.
Nutrition
Nutrition is important in patients with COPD as many of them are malnourished and
underweight, although marked cachexia is now uncommon. Several patients with
COPD are obese because of reduced physical activity. They should lose weight,
particularly if they have sleep disturbances, metabolic syndrome or frank type II
diabetes. Antioxidant vitamin supplements should also be indicated. The place of
androgens and anabolic steroids to build muscle bulk in COPD has not been
established.
Pulmonary Rehabilitation
Rehabilitation concerns prevention of deconditioning and allowing the patient to
cope with his/her disease. Rehabilitation programs are successful in prospective
65
randomized trials in the terms of increased performance and quality of life, even
though they may not improve lung function.194 Patients with moderate-to-severe
COPD should be considered for pulmonary rehabilitation programs, which include
educational advice and physiotherapy. There is evidence that pulmonary
rehabilitation also increases the efficacy of bronchodilator therapy.
Artificial Ventilation
Artificial ventilation devices have improved enormously. Non-invasive ventilation
using nasal intermittent positive pressure ventilation has been an important
advancement in the management of acute exacerbations of COPD in hospital and
more recently for the control of hypercapnic respiratory failure at home, thus
reducing the need for hospitalization. Nasal intermittent positive pressure ventilation
corrects the hypercapnia and respiratory acidosis, while resting the respiratory
muscles. Good results in the management of acute exacerbations have been
reported, with significant reduction in mortality and time spent in hospital.
Surgery
Several surgical techniques have been successfully applied to more severe
emphysema. These include heart-lung transplantation, now largely replaced by
single-lung transplantation in carefully selected patients.195 Lung volume reduction
surgery (LVRS) by excision of badly affected emphysematous lung is effective in
highly selected patients with bilateral predominantly upper lobe emphysema and
evidence of air trapping. There is sustained improvement in lung function and
reduction in symptoms with a reduction in exacerbations. Patients with a very poor
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diffusing capacity had an increased mortality. Therefore, patient selection is very
important. More recently bronchoscopic lung volume reduction surgery has been
developed to avoid the surgical morbidity and mortality of LVRS. Several devices,
including valves, coils and irreversible non-blocking techniques (bronchoscopic
thermal vapor ablation, polymeric lung volume reduction) designed to collapse and
remodel hyperinflated lung are currently in development.
RELATED STUDIES:
STUDIES ON DOXOFYLLINE:
1. A Randomised control trial in COPD pts conducted by Dolcetti et al  showed
doxofylline increased FEV1 when compared with placebo.no signs of
adverse effects were found.
2. A retrospective study conducted by Bagnato et al  showed that doxofylline
use caused adverse event of 6% and patient dropout on relation to adverse
events were 5%
3. Goldstein MF et al conducted a landmark randomized controlled trial  where
doxofylline showed a significant increase in FEV1 compared to placebo
group.
4. Bagnato et al conducted a study in the age group of 6-12 years showed
significant improvement of the spirometric parameters in the doxofylline
group.
67
5. Villani F et al conducted a trial showing that doxofylline significantly
increased the FEV1 Value compared to the placebo arm  but adverse effects
like dyspepsia and anxiety were reported.
COMPARATIVE STUDIES ON THEOPHYLLINE AND DOXOFYLLINE:
1. Rupali Bajrang et al conducted a  study ,Comparating the Efficacy And
Safety Of Doxofylline Versus Theophylline in Bronchial Asthma And Copd
Patients at government medical college and hospital, Aurangabad  for one
month and  it was found that FEV1, FEF and PEFR was significantly
improved in doxofylline group than theophylline group.
2. MD Faiz Ak ram et al conducted  arandomized, prospective and open label
study in patients of COPD in TB chest department of a medical college
hospital . 154 patients were divided in theophylline group and doxofylline
group   Results of the study showed that there was no statistically significant
difference with respect to spirometric variables and symptom score in the two
groups and there was no significant difference in two groups with respect to
side effects (p>0.05).
3. Goldstein MF et al conducted a landmark randomized controlled trial  where
doxofylline was as effective as theophylline in broncho dilating effect but
with lesser adverse effects.
4. Comparative study of the efficacy and safety of theophylline and doxofylline
in patients with bronchial asthma and chronic obstructive pulmonary disease
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done by Dushyant Lal et al in Vishwanathan Chest Hospital, Delhi with 60
patients showed that doxofylline was more effective as evidenced by
improvement in PFT as well as clinical symptoms, and reduced incidence of
adverse effects and emergency bronchodilator use.
5. Panduranga Rao Nagawaram et al conducted an open label, randomized,
prospective parallel group study of 12 weeks duration in patients of COPD
comparing  theophylline and doxofylline in TB chest department of Osmania
medical college hospital.There was no statistically significant difference with
respect to spirometric variables and symptom score in the two groups and no
significant difference in two groups with respect to side effects
6. Margay SM et al conducted a clinical trial to study the efficacy and safety of
doxophylline and theophylline in bronchial asthma and COPD and concluded
that both theophylline and doxofylline improved the lung function tests and
symptoms in patients of mild Bronchial Asthma, but doxofylline has a better
profile in terms of safety.
7. Comparative Study of Efficacy and Adverse Effect Profile of Theophylline
and Doxofylline in Patients with COPD by Kurli Sankar et al  showed that
doxofylline can be used as an effective alternative to patients who cannot
tolerate the adverse effects of theophylline.
With the above extensive literature review, this study was designed to compare the
efficacy and safety of doxofylline and theophylline and to prove the advantages of
doxofylline.
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AIM OF THE STUDY
To compare the safety and efficacy of oral doxofyline with theophylline in
Grade 1-2 COPD patients.
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MATERIALS AND METHODS
STUDY DESIGN:
Randomised, Comparative, Open label, Single centre, Prospective Parallel group
Study.
STUDY CENTRE:
Department of Chest Medicine in Tirunelveli Medical College Hospital.
STUDY POPULATION:
Grade1-2 COPD patients (Based on GOLD Criteria) attending the outpatient
department of Chest Medicine in Tirunelveli Medical College Hospital
STUDY PERIOD:
One Year from April 2016 to March 2017
SAMPLE SIZE:
60(each group – 30)
INCLUSION CRITERIA:
1. All the stable patients who were diagnosed clinically with COPD by the
outpatient department of the hospital were enlisted and those having the FEV1
within 50% to 80% of the predicted FEV1 for their age and height and showed non
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reversibility of FEV/FVC<70% Value, 20 minutes after inhalation of two puffs (400
microgram) of salbutamol are taken up for the study.
2. Adults, 18 years of age and above. Irrespective of gender.
3. Patients who have given written informed consent to participate in the study.
EXCLUSION CRITERIA:
1. Clinically significant cardiovascular diseases, including a history of congestive
cardiac failure, angina pectoris within previous 1 year.
2. Convulsive disorders.
3. Clinical significant gastro-intestinal diseases including active peptic ulcers within
preceding 1 year.
4. Renal diseases, hepatic diseases, and hematologic diseases
5. Known infection with human immunodeficiency virus.
6. Presence of any acute illness.
7. Sensitivity to theophylline or theophylline like agents.
8. Pregnant and Lactating women.
9. Patients on warfarin and digoxin.
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SCREENING:
GENERAL EXAMINATION
Nutritional status
Body weight
Height
Ankle edema
Blood pressure measurement
Respiratory examination
Cardiovascular examination
Abdominal examination
LABORATORY INVESTIGATIONS
Blood Urea
Serum creatinine
Serum sodium and potassium
Serum calcium
X-Ray chest
ECG
TREATMENT PROTOCOL AND FOLLOW UP :
Patients who fulfilled the inclusion criteria were enrolled in the study. .For all
patients, their current medical history and Diagnosis, COPD Grade was noted.
Detailed medical history with general and systemic examination was done. All the
baseline investigations, Hemoglobin, total leucocyte count, differential leucocyte
count, liver function test, kidney function test were done. Pulmonary function test
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(spirometry) assessments, COPD Assessment Test (CAT) Questionnaire assessment
were performed for every patient. Demographic data was collected from all the
patients. After enrollment, each group was randomized using computerized
randomized tables and divided into two subgroups. Group I patients were
administered Theophylline, 100 mg twice daily and group II patients were
administered doxofylline 400 mg twice daily, orally for a duration of 12 weeks.
Both Group I and Group II patients were on oral short acting beta 2 agonist
salbutamol 4 mg BD. Follow up visits will be at 6 weeks and at 12 weeks. Patients
were instructed to attend the chest medicine clinic fortnightly to receive drugs for 14
days and they were instructed to report immediately in case of any adverse event.
Adherence was monitored by pill count.
Clinical response was assessed in both Group I and Group II patients at every visit.
PARAMETERS ASSESSED:
 Pulmonary function tests at baseline, 6 weeks and 12 weeks
 COPD Assessment Test (CAT) Questionnaire assessment at baseline, 6
weeks and 12 weeks
 Urea,creatinine
 serum sodium and potassium
 serum calcium
 ECG
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STATISTICAL ANALYSIS
For the quantitative data, forced vital capacity (FVC), forced expiratory volume in
one second (FEV1) and FEV1/FVC, mean±SD values of all the variables were
analysed. The significant differences among various points of time (0, 6 weeks and
12 weeks) were calculated by using analysis of variance (ANOVA) with repeated
measures. The differences between values of a variable at two different time
intervals were tested by the post-hoc test (Bonferroni). The differences in variables
(FVC, FEV1, FEV1/FVC and symptom score) between the two groups of drugs
were analyzed by Student’s t-test. The above statistical analysis was done using
SPSS version 23.0
Adverse effects were analysed using descriptive statistics
p-Values of < 0.05 were considered significant in all the cases.
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INSTITUTIONAL ETHICS COMMITTEE APPROVAL
SCREENING
REGISTRATION of subjects according to inclusion criteria
RANDOMISATION
TREATMENT GROUP 1
THEOPHYLINE
100mg twice daily
TREATMENT GROUP 2
DOXOFYLINE
400 mg twice daily
FOLLOW UP VISITS
AT 6 WEEKS ,12 WEEKS
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RESULTS
Table - 1
BASELINE CHARACTERISTICS
VARIABLES DOXOFYLLINE THEOPHYLLINE P
VALUE
AGE 63.2±12.1 61.3±10.2 0.709
GENDER
MALE 19 18
0.667
FEMALE 11 12
SOCIO ECONOMIC
STATUS
3.7±0.48 3.6±0.52 0.660
COUGH
DURATION
6.70±5.75 4.60±4.41 0.379
GRADES OF
DYSPNEA
2.4±1.07 2.7±0.95 0.517
FEV1 58.9±20.09 53.3±29.39 0.625
FVC 76.3±22.63 76.5±23.17 0.985
FEV1/FVC 75.0±13.59 65.8±14.69 0.163
CAT Score 15.3±8.30 16.9±9.27 0.689
Table 1: shows the baseline characteristics of the two groups were
given and their p value is not significant and hence comparable.
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Figure - 1
PERCENTAGE OF CASES SHOWING EXPOSURE TO
VARIOUS RISK FACTORS OF COPD
Figure 1: depicts the percentage population among the study groups
who were exposed to various risk factors of COPD like tobacco
exposure,exposure to biomass fuel and occupational dust exposure.
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Table 2
COMPARISON OF FEV1 AND FVC FROM BASELINE TO 12 WEEKS IN
DOXOFYLLINE GROUP (WITHIN GROUP)
Table 2 : shows the mean and standard variation of FEV1and FVC for doxofylline
group and it shows statistically significant improvement from baseline to 12 weeks
Variables VISITS
Mean Std. Deviation
Mean
difference
P value
FEV1
BASELINE 58.9000 20.09118 _ _
6 WEEKS 67.1000 15.97533
-8.200 0.086
12 WEEKS 74.0000 15.54921
-15.100 0.018
FVC
BASELINE 76.3000 22.63748 _ _
6 WEEKS 88.0000 27.27636 -11.700 0.231
12 WEEKS 93.5000 24.70380 -17.200 0.044
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Table 3
COMPARISON OF FEV1/FVC FROM BASELINE TO 12 WEEKS IN
DOXOFYLLINE GROUP (WITHIN GROUP)
Table 3:  shows the mean and standard variation of FEV1/FVC for doxofylline
group and it shows improvement at each visit from baseline but statistically not
significant.
FEV1/FVC
Mean
Std.
Deviation
Mean
difference
p value
BASELINE 75.0000 13.58921 _ _
6 WEEKS 77.9000 14.13781 -2.900 1.000
12 WEEKS 80.5000 13.07457 -5.500 0.508
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Figure 2
COMPARISON OF SPIROMETRIC CHANGES OF MEAN VALUES AT
BASELINE, 6 WEEKS AND 12 WEEKS IN DOXOFYLLINE GROUP
SPIROMETRIC VARIABLE
Figure 2: compares the mean spirometric variables – FEV1, FVC and FEV1/FVC
in Doxofylline group. It shows significant improvement from the baseline to 12
weeks in FEV1 and FVC but not in FEV1/FVC
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Table 4
COMPARISON OF CAT SCORE FROM BASELINE TO 12 WEEKS IN
DOXOFYLLINE GROUP (WITHIN GROUP)
CATSCORE
Mean Std. Deviation
Mean
Difference
(I-J) P value
BASELINE 15.3000 8.30060
_ _
6 WEEKS 13.0000 7.91623 2.300 0.070
12 WEEKS 11.8000 8.10761 3.500* 0.003
Table 4: shows the mean and standard variation of CAT Score for doxofylline
group and it shows statistically significant improvement from baseline to 12 weeks.
82
Table 5
COMPARISON OF FEV1 AND FVC FROM BASELINE TO 12 WEEKS IN
THEOPHYLLINE GROUP (WITHIN GROUP)
Table 5: shows the mean and standard variation of FEV1 and FVC for theophylline
group.  The Table shows statistically significant improvement of FEV1 from
baseline to 12 weeks but for FVC, though there is improvement in mean values
from baseline to 12 weeks, it was not statistically significant.
Variables VISITS Mean
Std.
Deviation
Mean
Difference
(I-J) P value
FEV1
BASELINE 53.3000 29.39029
6 WEEKS 67.4000 36.96605 -14.100* .031
12 WEEKS 68.6000 36.65818 -15.300* .015
FVC
BASELINE 76.5000 23.16727
6 WEEKS 84.8000 22.92888 -8.300 .704
12 WEEKS 86.1000 22.79108 -9.600 .486
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Table 6
COMPARISON OF FEV1/FVC FROM BASELINE TO 12 WEEKS IN
THEOPHYLLINE GROUP (WITHIN GROUP)
FEV1/FVC
Mean Std. Deviation
Mean
Difference
(I-J) P value
BASELINE
65.8000 14.68786
_ _
6 WEEKS
70.8000 16.52473 -5.000 1.000
12 WEEKS
70.8000 16.52473 -5.000 1.000
Table 6: shows the mean and standard variation of FEV1/FVC for theophylline
group and it shows improvement from baseline to 12 weeks but statistically not
significant.
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Figure 3
COMPARISON OF SPIROMETRIC CHANGES OF MEAN VALUES AT
BASELINE, 6 WEEKS AND 12 WEEKS IN THEOPHYLLINE GROUP
SPIROMETRIC VARIABLES
Figure 3: compares the mean spirometric variables – FEV1, FVC and FEV1/FVC
in Theophylline group. It shows significant improvement from the baseline to
1weeks in FEV but not in FVC,FEV1/FVC.
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Table 7
COMPARISON OF CAT SCORE FROM BASELINE TO 12 WEEKS IN
THEOPHYLLINE GROUP (WITHIN GROUP)
Table 7: shows the mean and standard variation of CAT Score for theophylline
group and it shows statistically significant improvement  at each visit from baseline
to 12 weeks.
.
CATSCORE
Mean Std. Deviation
Mean
Difference (I-
J) P value
BASELINE
16.9000 9.27901
_ _
6 WEEKS
12.5000 7.41245 4.400* 0.003
12 WEEKS
11.5000 7.39745 5.400* 0.002
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Figure 4
COMPARISON OF MEAN VALUES OF CAT SCORE AT AT BASELINE,6
WEEKS AND 12 WEEKS IN DOXOFYLLINE AND THEOPHYLLINE
GROUP
Figure 4: compares the mean values of CAT Score at baseline,6 weeks and 12
weeks in theophylline group and was found to be significant. Similarly for
Doxofylline group, mean values of CAT Score at baseline,6 weeks and 12 weeks
was found to be significant.
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Table 8
COMPARISON OF CHANGE IN CAT SCORE BETWEEN DOXOFYLLINE
AND THEOPHYLLINE AT 12 WEEKS
GROUP N Mean
Std.
Deviation t df P value
CAT
SCORE
DOXOFYLLINE 30 11.800 8.10761
.086 58 0.932THEOPHYLLINE 30 11.500 7.39745
Table 8: shows there was a increase in the mean value of CAT Score in doxofylline
group in absolute numbers than the theophylline group but it was not statistically
significant.
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Figure 5
COMPARISON OF SPIROMETRIC CHANGES OF MEAN VALUES AT 12
WEEKS BETWEEN DOXOFYLLINE AND THEOPHYLLINE GROUP
Figure 5: compares the mean spirometric variables – FEV1, FVC and FEV1/FVC
between the two groups. Doxofylline group shows better mean values  in absolute
numbers than theophylline group but not significant.
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Table 9
COMPARISON OF CHANGE IN SPIROMETRIC VARIABLES BETWEEN
DOXOFYLLINE AND THEOPHYLLINE AT 12 WEEKS.
Variables Doxofylline Theophylline
t df P value
Mean
Std.
Deviation Mean
Std.
Deviation
FEV1 74.0000 15.54921 68.6000 36.65818 0.429 58 0.673
FVC 93.5000 24.70380 86.1000 22.79108 0.696 58 0.495
FEV1/FVC 80.500 13.074 70.800 16.524 1.456 58 0.163
Table 9: shows there was a increase in the mean value of spirometric variables –
FEV1,FVC and FEV1/FVC in doxofylline group in absolute numbers than the
theophylline group but it was not statistically significant.
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Figure 6
COMPARISON OF ADVERSE EFFECTS OBSERVED BETWEEN
DOXOFYLLINE AND THEOPHYLLINE GROUP PATIENTS
NO. OF PATIENTS
Figure 6:  shows the total number of patients who reported adverse drug events in
both doxofylline and theophylline group were depicted here. The number of ADR in
theophylline group is higher compared with doxofylline group patients. The most
common adverse effect observed in both groups was dyspepsia.
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DISCUSSION
Obstructive diseases of the airways are characterized by an increase in resistance to
airflow to partial or complete obstruction at any level, from the trachea and larger
bronchi to the terminal and respiratory bronchioles. The major obstructive disorders
are COPD (emphysema and chronic bronchitis) and bronchial asthma. COPD is a
major health problem worldwide.196 Its prevalence is being recognized increasingly
in countries at all levels of development. In large areas of the world where indoor air
pollution is generated by burning biomass for heating and cooking, COPD is
prevalent among nonsmokers, especially women.197 Global prevalence of COPD
based on Current epidemiological situation is 11.7%(8.4%–15.0%)30Prevalence of
COPD has been constantly rising worldwide. Now COPD has become the fourth
leading cause of death. In patients with these diseases, PFTs show limitation of
maximal airflow rates during expiration, usually measured by FEV1. Expiratory
airflow obstruction may result either from anatomic airway narrowing, such as that
classically observed in asthma, or from loss of elastic recoil of the lung, which
characteristically occurs in emphysema.198COPD is a complex disease characterized
by progressive and partly irreversible airway obstruction and ubiquitous chronic
inflammation in the lung. Initial clinical symptoms are shortness of breath and
occasional cough. As the disease progresses, difficulty in breathing becomes more
pronounced, with limitation on even modest physical exertion, thereby disrupting
daily life .
92
The comparison of the clinical efficacy and safety profile of doxofylline with
theophylline in the Indian population was less studied. The present study was
designed to compare the clinical efficacy and safety of oral theophylline and
doxofylline in patients with Grade1-2 COPD (Based on GOLD Criteria).
Diagnosis of COPD is made on clinical judgment based on a combination of history,
physical examination and confirmation of the presence of airflow obstruction using
lung function testing (spirometry). Spirometry provides objective information about
pulmonary functions and assesses the result of therapy199
Bronchodilators are the main stay in the treatment option for symptom relief in
COPD. Methylxanthines are emerging as effective option in the treatment of
obstructive airway diseases and drugs such as theophylline and doxofylline have
been used orally in these disorders. Their effect is a generalised reduction of airway
obstruction that decreases the overall resistance of the airways, improves blood gas
exchange and reduces the dyspnea It has been recognised that these drugs may
provide benefits above and beyond the usual bronchodilationUnfortunately, therapy
with theophylline is generally associated with a number of adverse events, affecting
the cardiovascular system, the central nervous system and the gastrointestinal
system. Doxofylline is a newer xanthine bronchodilator that differs from
theophylline. Although doxofylline shares most of the characteristics of the
methylxanthine drugs, experimental studies has shown that it is associated with less
extra-respiratory effects than theophylline6,7,8. It is suggested that decreased
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affinities toward adenosine A1 and A2 receptors may account for the better safety
profile of doxofylline9
In our study, the mean age of patients in doxofylline group was 63.2±12.1 and the
mean age of patients in theophylline group was 61.3±10.2. MD Faiz et al in their
comparative clinical study with doxofylline and theophylline also did their study in
the age group ranged from 54 to 77 years.200 The percent of males in doxofylline
group was 63% and in theophylline it was 60%.Low socio economic status is a
known risk factor for COPD. Prescott et al in their study, Socioeconomic status,
lung function and admission to hospital for COPD reported that the risk of
developing COPD was inversely proportional to socioeconomic status.201
Similarly,in our study based on modified kuppusamy scale, the patients were from
low socioeconomic class ranging from scale 3 to 4.The mean duration of cough was
6.7±5.75 years in doxofylline group and 4.60±4.41 in theophylline group. we have
used medical research council scale for grading dyspnea and the mean grade was
2.4±1.07 for doxofylline group and 2.7±0.95 for theophylline group. Spirometric
parameters were assessed at the start of the study .The mean FEV1 value for
doxofylline group was 58.9±20.09 and for theophylline group, it was
53.3±29.39.The mean FVC value for doxofylline group was 76.3±22.63 and for
theophylline group it was 76.5±23.17.the mean FEV1/FVC value for doxofylline
group was 75±13.59 and for theophylline group it was 65.8±14.69. The COPD
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Assessment Test score was also assessed at the baseline and the mean score for
doxofylline was found to be 15.3±8.3 and for theophylline it was 16.9±9.27.
There was no significant difference between the two treatment groups in baseline
characteristics indicating a homogenous population.
Our study showed that the mean values of FEV1 in doxofylline group increased to
74% at the end of the study (12weeks) as compared to 6weeks value (67.1%) and
baseline value (58.9%). The improvement from baseline to 12 weeks was
statistically significant (p=0.018). The mean value of FVC was increased to 93.5%
at 12 weeks compared to 6 weeks value of 88% and baseline value of 76.3%.
Likewise the improvement from baseline to 12 weeks was statistically significant
(p=0.044). In our study though there was a significant improvement of FEV1 and
FVC from baseline to 12 weeks , the improvement observed when the comparison
was between baseline and 6 weeks it was not significant. It takes 12 weeks to get
significant improvement of FEV1 and FVC in the doxofylline group. The mean
values of FEV1/FVC in doxofylline group increased to 80.5% at 12 weeks as
compared to 6 weeks value (77.9%) and baseline value (75%).Though there was an
actual increase in numbers for the mean value, it was not statistically significant.
In our study, the mean values of FEV1 in theophylline group increased to 68.6% at
the end of the study (12weeks) as compared to 6weeks value (67.4%) and baseline
value (53.3%). The improvement from baseline to 12 weeks was statistically
significant (p=0.015). The mean value of FVC was increased to 86.1% at 12 weeks
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compared to 6 weeks value of 84.8% and baseline value of 76.5%. The mean values
of FEV1/FVC in theophylline group increased to 70.8% at 12 weeks as compared to
baseline value (65.8%).Though there was an actual increase in numbers for the
mean value for both FVC and FEV1/FVC, it was not statistically significant. These
results are consistent with the study of Santra CK at Burdwan Medical College and
Midnapore Medical College in West Bengal done as an open randomized
multicentric trial.202 In a study conducted by MD Faiz et al  in 154 COPD patients
comparing  doxofylline with theophylline wherein individually both doxophylline
and theophylline show statistically significant improvement of spirometric
parameters from baseline.200
At the end of our study, when the spirometric assessment was compared between
the two treatment groups, the mean value of FEV1 in doxofylline group was
74±15.54 compared with mean value of FEV1 of theophylline group 68.6±36.65
and it was statistically not significant.(p =0.673).The mean FVC in doxofylline
group was 93.5±24.7 and for theophylline group it was 86.1±22.79. The p value for
FVC between the groups was 0.495 and it was not significant. The mean value of
FEV1/FVC in doxofylline group was 80.5±13.07 compared with mean FEV1/FVC
of theophylline group 70.8±16.52.In our study, although Doxofylline group showed
better mean spirometric values – FEV1, FVC and FEV1/FVC in absolute numbers
than theophylline group but were not statistically significant.
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Our results are consistent with those of previous studies that assessed the effects of
orally administered doxofylline in the management of patients with COPD In 2016 ,
Panduranga rao et al in a study of 40 patients  with COPD comparing doxofylline
with theophylline reported similar results wherein both groups significantly
improved spirometric parameters within their group but not significant when
compared between the two groups(p>0.05).203 Marino O et al. compared doxofylline
with theophylline  in 25 COPD patients and concluded that the spirometric variables
had improved in both treatment .Melillo et al examined the clinical effects of
doxofylline in 139 patients with COPD treated in a double-blind randomized
fashion with either oral doxofylline. or theophylline.204 Both doxofylline and
theophylline treatments significantly improved all pulmonary function parameters as
compared to baseline(p<0.05), but were not statistically different from each other.
The COPD Assessment test is a standard unidimensional measure of health
impairment in COPD. The mean CAT Score for doxofylline group decreased from
15.3±8.3 at the baseline to 13±7.91 in 6 weeks and further decreased to 11.8±8.1 at
12 weeks showing statistically significant improvement (p value =0.003). The mean
CAT Score for theophylline group  decreased from 16.9±9.27 at the baseline to
12.5±7.41 in 6 weeks and further decreased to 11.5±7.3 at 12 weeks showing
statistically significant improvement (p value =0.002).
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At the end of the study,there was a increase in the mean value of CAT Score in
doxofylline group(11.8±8.10) than the theophylline group (11.50±7.39) but it was
not statistically significant(p value=0.932)
The number of ADR in theophylline group is higher compared
with doxofylline group patients. Goldstein MF et al in his multicenter clinical trial
comparing doxofylline and theophylline reported that even maximum dosage of
doxofylline is better tolerated than theophylline.205 The most common adverse effect
observed in both groups was dyspepsia. Among the two groups, theophylline
induced dyspepsia was higher than the doxofylline group.In the study done by
panduranga et al in 2016, showed that gastro intestinal symptoms were the most
common in both theophylline and doxofylline groups203
One of the major limitations of theophylline is its nonselectivity for the
phosphodiasterase enzyme. Theophylline has an antagonistic action on the
adenosine A1, A2a and A2b receptors, which is responsible for its cardiac and
central nervous system stimulatory side effects. Doxofylline has been reported to
have less affinity for the adenosine receptor and it has been claimed to have a better
safety profile. It has been claimed to have a decreased affinity towards the
adenosine A1 and A2 receptors. doxofylline improves spirometric parameters and
improves the obstructive symptoms  of COPD patients similar to theophylline  but
not significantly better than theophylline. So doxofylline is as effective as
theophylline but with a better safety profile. In 2015,Margay SM et al in his study of
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100 patients of obstructive lung disease also reported that theophylline group
patients reported higher rates of adverse effects compared to doxofylline.206 From
these results in our study, doxofylline seemed to be a good alternative to
theophylline in the treatment of chronic obstructive pulmonary disease.
LIMITATIONS OF STUDY
Sample size was not adequate compared with the rising prevalence of COPD.  This
being a short term study further long term follow up was not done. Long term
follow up studies may bring more enduring results.
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CONCLUSION
Based on the results of this we conclude that,
 Doxofylline is found to be equally efficacious when compared to
theophylline in the treatment of Grade 1-2 COPD(GOLD Criteria).
 Doxofylline has a better safety and tolerability profile when compared to
theophylline.
 Doxofylline would offer an equivalent and safer alternative to theophylline in
the management of COPD.
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APPENDIX –I
INFORMED CONSENT FORM
Study Title :
AN OPEN LABELLED, RANDOMISED, PROSPECTIVE STUDY COMPARING THE
EFFICACY AND SAFETY OF DOXOFYLLINE WITH THEOPHYLLINE IN COPD PATIENTS.
Study Number _______________
Subject's Full Name ___________
Date of Birth/Age___________
Address _________________
1. I confirm that I have read and understood the information sheet dated for the above study and
have had the opportunity to ask questions. OR I have been explained the nature of the study by
the Investigator and had the opportunity to ask questions
2. I understand that my participation in the study is voluntary and that I am free to withdraw at
any time, without giving any reason and without my medical care or legal rights being affected.
3. I understand that the sponsor of the clinical trial/project, others working on the Sponsor's
behalf,the Ethics Committee and the regulatory authorities will not need my permission to look at
my health records both in respect of the current study and any further research that may be
conducted in relation to it, even if I withdraw from the trial. However, I understand that my
Identity will not be revealed in any information released to third parties or published.
4. I agree not to restrict the use of any data or results that arise from this study provided such a
use is only for scientific purpose(s)
5. I agree to take part in the above study
Signature (or Thumb impression) of the Subject/Legal Representative: ____________________
Signatory's Name _______________________Date __________________________
Signature of the Investigator ______________ Date __________________________
Study Investigator's Name ________________ Date __________________________
Signature of the Witness _________________Date __________________________
Name of the Witness
úSôVô°LÞdÏ A±®l× Utßm Jl×Rp T¥Ym
UÚjÕY Bn®p TeúLtTRtÏ
BnÜ ùNnVlTÓm RûXl×:
TeÏ ùßTY¬u ùTVo :
TeÏ ùTßTY¬u YVÕ :
TeÏ ùTßTYo
CRû] Ï±dLÜm
1 Sôu úUúX Ï±l©hÓs[ UÚjÕY Bn®u
®YWeLû[ Sôu T¥jÕ ×¬kÕ ùLôiúPu.
GuàûPV NkúRLeLû[ úLhLÜm ARtLô] RÏkR
®[dLeLû[ ùT\Üm YônlT°dLlThÓs[Õ G]
A±kÕ ùLôiúPu.
2 Sôu CqYôn®p Ru²fûNVôL Rôu TeúLt¡ú\u.
GkR LôWQj§]ôúXô GkR LhPj§Ûm, GkR NhP
£dLÛm EhTPôUp Sôu CqYôn®p CÚkÕ ®X¡
ùLôs[Xôm Gußm A±kÕ ùLôiúPu.
3 CkR BnÜ NmTkRUôLúYô. CûRf NôokÕ úUÛm
BnÜ úUtùLôsÞm úTôÕm CkR Bn®p TeÏ
ùTßm UÚjÕYo GuàûPV UÚjÕY A±dûLûV
TôolTRtÏ GuàûPV AàU§ úRûY«pûX G]
A±kÕ ùLôs¡ú\u. Sôu Bn®p CÚkÕ ®X¡d
ùLôiPôÛm CÕ ùTôÚkÕm G] A±¡ú\u.
4 CkR An®u êXm ¡ûPdÏm RLYûXúVô.
Ø¥ûYúVô TVuTÓj§d ùLôs[ UßdL UôhúPu.
5 CkR Bn®p TeÏ ùLôs[ Jl×d ùLôs¡ú\u.
G]dÏ ùLôÓdLlThP A±ÜûWL°uT¥ SPkÕ
ùLôsYÕPu BnûY úUtùLôsÞm UÚjÕ
A¦dÏ EiûUÙPu CÚlúTu G]
Eß§V°d¡ú\u. Gu EPp SXm Tô§dLlThPôúXô.
ApXÕ G§oTôWôR YZdLj§tÏ Uô\ô] úSônÏ±
ùRuThPôúXô EPú] CûR UÚjÕY A¦«Pm
ùR¬®lúTu G] Eß§ A°d¡ú\u.
TeúLtTY¬u ûLùVôlTm /……………..…….. CPm ……………….. úR§
................LhûP ®Wp úWûL
TeúLtTY¬u ùTVo Utßm ®XôNm ………………………………………………
BnYô[¬u ûLùVôlTm /……………..…….. CPm ……………….. úR§
................
BnYô[¬u ùTVo ……………………………………………………………………..
ûUVm…………………Lp®V±Ü CpXôRYtÏ (ûLúWûL ûYjRYoLÞdÏ) CÕ
AY£Vm úRûY
Nôh£«u ûLùVôlTm /……………..…….. CPm ……………….. úR§ ................
ùTVo Utßm ®XôNm …………………………………………………………
NehahspfSf;F mwptpg;G kw;Wk; xg;Gjy; gbtk;
(kUj;Jt Ma;tpy; gq;Nfw;gj;w;F)
Ma;T nra;ag;gLk; jiyg;G:
gq;F ngWthpd; ngaH:
gq;F ngWthpd; taJ:
gq;F ngWth;
,jid 
Fwpf;fTk;
1. ehd; NkNy Fwpg;gpl;Ls;s kUj;Jt Ma;tpd; tptuq;fis gbj;J
Ghpe;J nfhz;Nld;. vd;Dila re;Njfq;fis Nfl;fTk;>
mjw;fhd jFe;j tpsf;fq;fis ngwTk; tha;g;gspf;fg;gl;Ls;sJ
vd mwpe;J nfhz;Nld;.
2. ehd; ,t;tha;tpy; jd;dpr;irahf jhd; gq;Nfw;fpNwd;. ve;j
fhuzj;jpdhNyh ve;j fl;lj;jpYk;> ve;j rl;l rpf;fYf;Fk;
cl;glhky; ehd; ,t;tha;tpy; ,Ue;J tpyfp nfhs;syhk; vd;Wk;
mwpe;J nfhz;Nld;.
3. ,e;j Ma;T rk;ge;jkhfNth> ,ij rhHe;J NkYk; Ma;T
Nkw;fhs;Sk; NghJk; ,e;j Ma;tpy; gq;FngWk; kUj;JtH
vd;Dila kUj;Jt mwpf;iffis ghHg;gjw;F vd; mDkjp
Njitapy;iy vd mwpe;J nfhs;fpNwd;. ehd; Ma;tpy; ,Ue;J
tpyfpf; nfhz;lhYk; ,J nghUe;Jk;; vd mwpfpNwd;.
4. ,e;j Ma;tpd; %yk; fpilf;Fk; jftiyNah> KbitNah
gad;gLj;jpf; nfhs;s kWf;f khl;Nld;.
5. ,e;j Ma;tpy; gq;F nfhs;s xg;Gf; nfhs;fpNwd; vdf;F
nfhLf;fg;gl;lmwpTiufspd; gb ele;J nfhs;tJld;> Ma;it
Nkw;nfhs;Sk; kUj;Jt mzpf;F cz;ikAld; ,Ug;Ngd; vd;W
cWjpaspf;fpNwd;. vd; cly; eyk; ghjpf;fg;gl;lhNyh> my;yJ
vjpHghuhj> tof;fj;jpw;F khwhd Neha;Fwp njd;gl;lhNyh
clNd ,ij kUj;Jt mzpaplk; njhptpg;Ngd; vd cWjp
mspf;Nwd;.
gq;Nfw;gthpd; ifnahg;gk; / ............................................,lk; ...........................................
fl;iltpuy; Nuif
gq;Nfw;gthpd; ngaH kw;Wk; tpyhrk; .....................................................................................
Ma;thshpd; ifnahg;gk; /................................................. ,lk; ..........................................
Ma;thshpd; ngaH .................................................................................................................
ikak; ........................................................................................................................................
fy;tpawpT ,y;yhjtw;F (ifNuif itj;jtHfSf;F) ,J mtrpak; Njit
rhl;rpapd; ifnahg;gk; /..................................................,lk; ..............................................
ngaH kw;Wk; tpyhrk; ................. ............................................................................................
1CASE RECORD FORM
NAME :                                                                                                       AGE/SEX :
ADDRESS:
CONTACT NO :
OCCUPATION :
SOCIO ECONOMIC STATUS :
NO. OF FAMILY MEMBERS :
PRESENTING ILLNESS:
VISIT-I VISIT-II VISIT-III
1. CHRONIC COUGH – DRY/PRODUCTIVE DRY/PROD. DRY/PROD.
DURATION :
2. SPUTUM PRODUCTION : YES/NO YES/NO                 YES/NO
DURATION :
3. DYSPNEA : PROGRESSIVE - YES/NO YES/NO                 YES/NO
WITH EXERCISE : WORSE- YES/NO YES/NO                 YES/NO
PERSISTENT- YES/NO YES/NO                  YES/NO
EXERCISE TOLERANCE:
ACTIVITY LIMITATION : YES/NO                            YES/NO YES/NO
H/O SLEEP DISTURBANCE : YES/NO. YES/NO                    YES/NO
EXPOSURE TO RISK FACTORS:
TOBACCO SMOKER – YES/NO.    DURATION :            PACK YEARS:
PASSIVE SMOKER : YES/NO
2IF STOPPED, HOW LONG?
SMOKE FROM HOME COOKING(BIOMASS) AND HEATING FUEL : YES/NO
OCCUPATIONAL DUST/CHEMICAL EXPOSURE: YES/NO
PAST HISTORY:
BIRTH WEIGHT:
H/O TUBERCULOSIS: YES/NO
H/O CHILDHOOD RESPIRATORY ILLNESS: YES/NO
H/O ASTHMA – YES/NO
H/O ALLERGY –YES/NO
H/O SINUSITIS/NASAL POLYP
H/O GERD : YES/NO
H/O CARDIOVASCULAR DISEASE/OSTEOPOROSIS/MUSCULOSKELETAL
DISORDERS/ LUNG MALIGNANCY
H/O DM/HTN
FAMILY HISTORY:
FAMILY H/O COPD: YES/NO
FAMILY H/O TB: YES/NO
OTHER RESPIRATORY ILLNESS FOR FAMILY MEMBERS :YES/NO
ANY FAMILY MEMBER WHO SMOKES : YES/NO
TREATMENT HISTORY:
VISIT-I                  VISIT-II            VISIT-III
H/O EXACERBATIONS: YES/NO YES/NO            YES/NO
FREQUENCY :
H/O HOSPITALISATION FOR RESP.ILLNESS: YES/NO YES/NO            YES/NO
USE OF STEROIDS / RESCUE MEDICATIONS: YES/NO           YES/NO            YES/NO
3CURRENT MEDICATIONS:
EXAMINATION :
HEIGHT:
WEIGHT:
PULSE:
BP:
ANKLE EDEMA : YES/NO
INVESTIGATIONS:
SPIROMETRY:
VISIT-I                             VISIT-II                        VISIT-III
FEV1:
FVC:
FEV1/FVC:
PEFR:
CHEST X-RAY:
ECG:
4BLOOD INVESTIGATIONS:
VISIT-I                             VISIT-II                        VISIT-III
Hb
TC
DC
ESR
UREA
CREATININE
SERUM ELECTROLYTES
SERUM Calcium
LIPID PROFILE
CAT SCORE :
VISIT-I                             VISIT-II                        VISIT-III
ADR RECORDING FORM
THEOPHYLLINE GROUP DOXOPHYLLINE GROUP
V1 V2 V3 V1               V2               V3
Nausea
Vomiting
Dyspepsia
Anorexia
Abdominal pain
Sweating
Irreg.Pulse Rhythm
Palpitation
Precordial Pain
Headache
Insomnia
Anxiety/Irritability
Seizure
others
0 1 2 3 4 5X
Your name: Today’s date:
How is your COPD?Take the COPDAssessmentTest™ (CAT)
This questionnaire will help you and your healthcare professional measure the impact COPD (Chronic Obstructive
Pulmonary Disease) is having on your wellbeing and daily life.Your answers, and test score, can be used by you and
your healthcare professional to help improve the management of your COPD and get the greatest benefit from treatment.
For each item below, place a mark (X) in the box that best describes you currently. Be sure to only select one response
for each question.
Example: I am very happy I am very sad
TOTALSCORE
SCORE
COPDAssessmentTest and CAT logo is a trademark of the GlaxoSmithKline group of companies.
© 2009 GlaxoSmithKline. All rights reserved.
I never cough 0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
I cough all the time
I have no phlegm (mucus)
inmychest at all
My chest is completely
full of phlegm (mucus)
My chest does not
feel tight at all
My chest feels
very tight
When I walk up a hill or
one flight of stairs I am
not breathless
When I walk up a hill or
one flight of stairs I am
very breathless
I am not limited doing
any activities at home
I am very limited doing
activities at home
I am confident leaving
my home despite my
lung condition
I amnotatall confident
leavingmyhomebecause
ofmylung condition
I sleep soundly
I don’t sleep soundly
because ofmy lung
condition
I have lots of energy I have no energy at all
COPD As essment Test and the CAT logo is  trade mark f the GlaxoSmithKline group of companies.
© 2 09 GlaxoSmithKline group of companies. All rights reserved.
Last Updated: February 24, 2012
ABBREVATIONS
COPD - Chronic obstructive Lung Disease
PFT - Pulmonary Function Test
CAT - COPD Assessment Test
GWAS - Genome Wide Association Study
A1AT - Alpha1Anti trypsin
GOLD - Global Initiative For Chronic Obstructive Lung Disease
BALF - Broncho Alveolar Lavage Fluid
DPI - Dry Powder Inhaler
MMRC - Modified Medical Research Council
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